VCAM-directed Immunoliposomes Loaded with Vascular– Disrupting Agents for Selective Targeting and Occlusion of the Tumor Vasculature : As a Novel Therapeutic Strategy by Gosk, Sara
VCAM-directed Immunoliposomes Loaded with Vascular–
Disrupting Agents for Selective Targeting and Occlusion of the 
Tumor Vasculature - As a Novel Therapeutic Strategy 
Dissertation
zur
Erlangung des Doktorgrades (Dr. rer. nat.) 
der
Mathematisch-Naturwissenschaftlichen Fakultät 
der
Rheinischen Friedrich-Wilhems-Universität Bonn 
vorgelegt von 
Sara Gosk 
aus Lisabon, Portugal 
Bonn, Januar 2007 

Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der 
Rheinischen Friedrich-Wilhelms-Universität Bonn 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gutachter: 
1. Prof. Dr. Gerd Bendas 
2. Prof. Dr. Ulrich Jaehde 
 
Tag der mündlichen Prüfung: 3. Juni 2008-05-30 
 
Diese Dissertation ist auf dem Hochschulschriftenserver der ULB Bonn elektronisch 
publiziert (http://hss.ulb.uni-bonn.de/diss_online). Erscheinungsjahr 2008. 

Zusammenfassung
Die gezielte Beeinflussung des Blutgefäßsystems eines soliden Tumors hat ein herausragendes 
Potential für verschiedene therapeutische Anti-Tumor-Strategien. So erscheint beispielsweise die 
Targetierung von Tumorgefäßen mittels Arzneistoffcarriern, die Wirkstoffe für eine Intervention 
der Endothel- bzw. Gefäßfunktion enthalten, als innovatives und neuartiges therapeutisches 
Prinzip. Für diese Targeting-Strategien müssen geeignete Carrier entwickelt werden. Als 
Zielstrukturen bieten sich solche endotheliale Epitope an, die spezifisch nur oder verstärkt von 
Gefäßsystem des Tumors exprimiert werden. Hierbei eignet sich besonders das vascular cell 
adhesion molecule 1 (VCAM-1). 
In der vorliegenden Arbeit wurden Immunliposomen (Antikörper-gekoppelte 
Liposomen), die gegen VCAM-1 gerichtet sind, hergestellt und hinsichtlich ihrer endothelialen 
Targetierung unter in vitro- und in vivo-Bedingungen untersucht. Als vaskulär aktive Wirkstoffe 
wurden Tumor Nekrose Faktor-alpha (TNF-Į) und der TNF-Į-induzierende Wirkstoff DMXAA 
in den Liposomen eingeschlossen. Diese Wirkstoffe sollten die Exprimierung von Tissue Faktor 
an den Endothelzellen und damit einen prokoagulativen Zustand in den Tumorgefäßen induzieren, 
der letztendlich mit der Kollabierung der Gefäßfunktion seine Anti-Tumor-Wirksamkeit entfaltet. 
Für die Untersuchungen des liposomalen Targetings wurden die Liposomen unter Verwendung 
verschiedener Ankerlipide mit anti-VCAM-Antikörpern gekoppelt und umfassend charakterisiert. 
Das Bindungsverhalten an zwei verschiedene Endothelzelllinien wurde unter in vitro-
Bedingungen mittels unterschiedlicher Techniken quantifiziert und erwies sich gegenüber 
Kontrollliposomen als positiv. 
Das Targeting der Immunliposomen unter in vivo-Bedingungen wurde in Colo 677-
Tumorxenograft-Mäusen untersucht. Dabei zeigten die Organverteilungs-Studien mittels Tritium-
gelabelter Liposomen, 30 Minuten bzw. 24 Stunden nach i.v. Injektion keine deutlichen Vorteile 
der VCAM-Immunliposomen hinsichtlich der Akkumulierung im Tumor. 
Fluoreszenzmikroskopische und immunhistochemische Untersuchungen der Tumoren zeigten 
aber, dass die Lokalisierung der Liposomen innerhalb der Tumoren sehr differierte. Während 
nicht-gerichtete Liposomen unspezifisch vom Tumorgewebe aufgenommen und dort akkumuliert 
wurden, binden die VCAM-gerichteten Immunliposomen hochspezifisch am Gefäßsystem. So 
konnte erstmals die Funktion von Immunliposomen als spezifischer vaskulärer Carrier 
verdeutlicht werden. 
  Die Wirkung von TNF-Į und DMXAA hinsichtlich einer verstärkten Tissue Faktor-
Exprimierung auf Endothelzellen wurde zuerst in Endothelzell-Kulturen verifiziert. Für den 
Einbau beider Wirkstoffe in Liposomen in ausreichendem Maße wurden die 
Herstellungsbedingungen optimiert, letztendlich resultierten Liposomen mit einer prozentualen 
Einschlussquote von 33% für TNF-Į und 18 % für DMXAA. Deren Wirkung wurde wiederum in 
den Colo 677-Mäusen hinsichtlich einer Wachstumsverzögerung der Tumoren analysiert. Es 
zeigte sich eindeutig, dass der Wachstums-verzögernde Effekt beider Wirkstoffe nur in 
Kombination mit dem VCAM-Targeting der Liposomen zum Tragen kommt. ZurAufklärung der 
molekularen Mechanismen der Anti-Tumor-Wirkung wurden verschiedene immunhistochemische 
Untersuchungen der behandelten Tumore angeschlossen. Die Anwendung eines TNF-Į-ELISA, 
eines Tissue Faktor-Stainings sowie die Verwendung des TUNEL-Assays zur Überprüfung der 
apoptotischen Aktivität konnten nicht eindeutig die Wirkung über die Tissue Faktor Exprimierung 
und damit Koagulation beweisen. 
Orientierende erste therapeutische Experimente mit TNF-Į-Liposomen zeigten aber nach 
24 und 72 Stunden erhöhte Tissue Faktor Werte im Tumor und stellen somit dieses postulierte 
Prinzip der Anti-Tumor-Wirkung als sehr aussichtsreich dar.  

Abstract
Targeting the tumor vasculature and selectively modifying endothelial functions with agents that 
exert their action on the tumor endothelial cells instead of the tumor cells themselves, is an 
attractive anti-tumor strategy. Polyethylenglycol modified immunoliposomes (IL) directed against 
vascular cell adhesion molecule 1 (VCAM), a surface receptor over-expressed on tumor vessels, 
were prepared and investigated the liposomal targetability in vitro and in vivo. The vascular 
destructing agents, tumor necrosis factor alpha (TNF-Į) and the TNF-Į inducing drug, DMXAA, 
are known to selectively target the tumor endothelium and induce a pro-coagulative state, which 
leads to a collapse of the tumor vasculature. The hypothesis that TNF-Į and DMXAA modulate 
the coagulative state of the endothelium through the up-regulation of tissue factor (TF) was 
investigated in vitro. VCAM-targeted and non-targeted liposomes loaded with either TNF-Į or 
DMXAA were formulated and upon administration tumor growth delay was investigated in vivo.
In vitro, VCAM antibodies conjugated to PEGylated liposomes through the cyanur 
anchor displayed specific binding to activated endothelial cells under static conditions, as well as 
under simulated blood flow conditions. The in vivo targeting of IL was analyzed in mice bearing 
human Colo 677 tumor xenografts 30 min and 24 h post i.v. injection. Whereas biodistribution 
studies using [
3H]-labeled liposomes displayed only marginal higher tumor accumulation of 
VCAM targeted vs. unspecific ILs; fluorescence microscopy evaluation revealed that their 
localization within tumors differed strongly. VCAM targeted ILs accumulated in tumor vessels 
with increasing intensities from 30 min to 24 h, while control ILs accumulated in the tumor tissue 
by passive diffusion. 
TNF-Į and DMXAA displayed a direct cytotoxic effect on the murine endothelial cells, 
and induced an 3-fold up-regulation of TF expression and activity after 6 and 12 hours in vitro.
TNF-Į and DMXAA were encapsulated into PEGylated liposomes with reasonable encapsulation 
efficiencies of 33 % and 18 %, respectively. Treatment of mice bearing human Colo 677 
xenografts with VCAM-targeted liposomes loaded with TNF-Į or DMXAA delayed the tumor 
growth compared to mice treated with non-targeted TNF-Į liposomes and non-treated mice. The 
mechanism behind the tumor growth delay was investigated using TNF-Į ELISA, TUNEL assay 
and TF immunohistochemistry, but did not add to the understanding of the mechanism behind the 
tumor growth delay. However, in a pilot experiment, tumors from mice treated with VCAM-
targeted TNF-Į liposomes displayed an increased TF expression after 24 and 72 hours, indicating 
that the mechanism behind the targeted TNF-Į liposomes might be the induction of TF. 
This is the first morphological evidence for selective in vivo targeting of tumor vessels 
using ILs and the first study to show that VCAM-targeted TNF-Į loaded liposomes have an 
antitumor effect in a human xenograft model.    
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1. Introduction 
1.1 Targeting solid tumors 
Solid tumors account for at least 85 % of cancerous deaths [Jain, 2005]. Therefore 
it is essential to develop treatments which kill tumor cells efficiently without damaging 
healthy cells. While traditional therapeutics, such as chemotoxic drugs or ionizing 
radiation, are very successful at killing tumor cells, they often fail to adequately 
discriminate between normal and malignant tissues. Thus, the severe side effects of these 
treatments often limit dosages to suboptimal levels or the duration of patient’s treatment, 
resulting in poor outcomes for the management of disease, quality of life, and overall 
survival. Also, tumor cell resistance in itself restricts the use and effect of cytostatic 
treatment in therapy and calls for targeted therapy forms. However, targeting tumor cells 
with monoclonal antibodies or immuno-conjugates is hampered by an uneven spatial 
distribution of the drugs in the tumor and inadequate accumulation of the injected 
antibodies at the target site [Christiansen and Rajasekaran, 2004].
1.1.1 Disadvantages of targeting the tumor cells in  solid tumors 
Solid tumors are composed of two distinct compartments: the malignant cells 
(parenchyma) and the supporting stroma. All solid tumors, regardless of their cellular 
origin require stroma and cannot grow beyond the minimal size of 1 - 2 mm without it 
[Dvorak et al, 1979; Folkman, 1986]. The stroma provides the vasculature needed for the 
supply of nutrients and oxygen. It also sets up a barrier that limits the influx of 
inflammatory cells. Therefore, the stroma acts as both a lifeline for tumor cells and a 
barrier that can regulate the interchange of cells and molecules with the host [Nagy et al,
1988]. There are at least three different physiological barriers that can inhibit therapeutics 
from reaching their target: the endothelial barrier, interstitial pressure, binding to stromal 
components and in some tumors the epithelial barrier [Christiansen and Rajasekaran, 
2004].
  The microenvironment of solid tumors is distinguished from normal tissue by 
exhibiting high interstitial fluid pressure (IFP), hypoxia and low extracellular pH 
[Tannock, 2001; Cairns et al., 2006]. The mechanisms responsible for this 
microenvironment are shown in Fig.1. In normal tissues the vascular system is regulated 
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by a balance of anti-angiogenetic and pro-angiogenetic factors which ensure the 
formation and maintenance of a functional and orderly network of blood vessels. In 
addition, a network of lymphatics drains away waste, such as cellular by-products and 
fluids. However, in solid tumors the balance is shifted towards the pro-angiogenetic, 
which leads to the formation of a disorganized vasculature with structural and functional 
abnormalities [Vauple, 2004]. The vasculature is often leaky due to an incomplete 
endothelial lining, to the lack of a layer of pericytes and to a leaky basal membrane 
[Vauple, 2004; Kumagai et al., 2006].
The tumor vessels are generally long and the vessel organization is often chaotic 
and heterogeneous with vessel hotspots, blind ends, arteriolar-venous shunts and plasma 
channels devoid of red blood cells [Dewhirst et al., 1996]. Solid tumors characteristically 
lack lymphatics, which leads to an increased accumulation of fluid and waste products in 
the tumor and further to an elevated IFP [Leu et al., 2000; Cairns et al., 2006] and a 
hydrostatic pressure gradient that causes fluid to move toward the periphery [Jain, 1987; 
Boucher et al., 1990]. The net outward flow inhibits the extravasation of  therapeutics, 
such as antibodies, immuno-conjugates or small drug molecules like doxorubicin 
[Lankelma et al., 1999] by reducing their penetration depth into the tumor by convection 
[Jain and Baxter, 1988; Burrows and Thorpe, 1994]. Thus, molecules can only penetrate 
the tumor by diffusion which is a slow process [Jain and Baxter, 1988]. 
Introduction 
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Figure 1. Schematic overview of biological barriers to effective treatment of solid tumors with monoclonal 
antibody-based immunotherapy. To reach a target antigen at the surface of a solid tumor, i.v. injected 
monoclonal antibody must first traverse the microvascular endothelium (A), and must subsequently contend 
with stromal barriers (B), and high interstitial fluid pressure characteristic of bulky tumor masses (C). 
Monoclonal antibodies may also confront epithelial barriers (D), including E-cadherin and tight junctional 
complexes that may have a profound impact on therapy [From Christiansen and Rajasekaran, 2004]. 
Another possible barrier against the homogenous distribution of 
antibodies/immuno-conjugates is the binding-site barrier [Burrows and Thorpe, 1994], in 
which monoclonal antibodies with high affinity for tumor antigens bind stably to the first 
encountered tumor antigen leading to a heterogeneous antibody delivery to the tumor 
cells [Adams et al., 2001; Juweid et al., 1992]. Sung et al., compared the spatial 
distribution of the diphtheria toxin (DT) and non-binding DT linked to a transferrin 
antibody. They found that the spatial distribution of the toxin was remarkably even 
throughout the tumor compared to the anti-transferrin coupled toxin, which was localized 
primarily in the perivascular space [Sung et al., 1993]. It was suggested that as the tumor 
cells in this study exhibited an extremely low number of DT receptors (< 3000/cell), DT 
was therefore not depleted rapidly by the perivascular tumor cells, whereas the tumor 
cells exhibited a high number of transferrin receptors (60,000 receptors/cell). Therefore, 
the immuno-toxin was quickly sequestered by the perivascular tumor cells [Sung et al.,
7
Introduction 
______________________________________________________________________________________ 
8
1993]. The difference in distribution could also have been due to the different sizes of the 
two tested molecules. Site-directed mutagenesis made it possible to compare the 
distribution of antibodies targeting the same epitope with different affinities. One study 
showed that single chain fragments (scFv) targeting the human epidermal growth factor 
recptor 2 (HER-2) with low affinity (3.2 x10
-7
 M) were distributed homogenously 
throughout the tumor, whereas the same scFv with a higher antigen affinity (1.5 x10
-11
 M) 
only traversed 2-3 cell diameters [Adams et al., 2001]. In summary, targeting the tumor 
cells with antibodies or immuno-conjugates is often hampered by a combination of an 
elevated IFP and sequestering of the antibody by various cellular barriers, such as the 
binding-site barrier.
Another problem with targeting tumor cells is the heterogeneous expression of 
antigens within a given tumor population and between various tumors [Burrows and 
Thorpe, 1994]. Epithelial cancer cells are known for their genetic instability generating a 
high degree of heterogeneity of the different tumor cell clones found in an individual 
tumor [Braun et al., 1999]. This is thought to impose a major limitation on treatments 
aimed at targeting the tumor cells. Much work has been put into refining the selectivity of 
monoclonal antibodies to target a larger fraction of the tumor population and successful 
candidates have indeed been found [Christiansen and Rajasekaran, 2004]. The therapeutic 
antibody Herceptin
®
 against HER-2, a member of class 1 receptor tyrosine kinases, is 
approved for treatment of metastatic breast cancer [Cobleigh et al., 1999]. Also, an 
antibody against the epithelial cellular adhesion molecule Panorex
®
 is being used in the 
treatment of colorectal cancer [Riethmuller et al., 1994; Riethmuller et al., 1998]. 
However, due to the heterogeneous expression of tumor antigens, different antibodies 
must be developed for different types of cancer. Extensive typing of the different cellular 
subtypes in the individual tumor needs to be carried out during treatment, making it 
difficult to develop a targeted therapy with a broad applicability [Burrows and Thorpe, 
1994].    
Targeting tumor cells in solid tumors has encountered several problems, such as 
heterogeneous distribution of antibodies and immuno-conjugates, and antigen 
heterogenicity within one tumor and between tumors. However, targeting the tumor 
vasculature instead of the tumor cells could prove to be an advantage because of several 
distinctive features, which will be described below.    
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1.1.2 Advantages of targeting the tumor vasculature 
Historically, the vasculature has been known as the “Achilles heel” of solid tumor 
growth [Siemann et al., 2005] and has been an indirect target in cancer therapy since the 
1700s, where bacterial infections were used in the treatment of cancer [Starnes, 1992]. As 
previously mentioned, the tumor needs to form new blood vessels by the process of 
angiogenesis in order to grow beyond a 2 mm [Brem et al., 1976; Folkman, 1986]. 
Angiogenesis occurs rarely in healthy adults, i.e. during the menstrual cycle, wound 
healing and embryonic development. The angiogenic tumor vasculature is therefore an 
interesting and selective target in solid tumors, present in both primary tumors and 
metastases [Bazan-Peregrino et al., 2007]. Vascular-targeted drugs inhibit or kill tumors 
by starvation with agents that target and selectively damage tumor endothelium by either 
inhibiting angiogenesis or inducing a vascular collapse as opposed to exerting a direct 
effect on the rapidly growing tumor cells, [Huang et al., 1997; Philipp et al., 2003; 
Siemann et al., 2005]. Vascular targeting looks promising for the delivery of drugs 
[Pastorino et al., 2003], genes [Hood et al., 2002] and radionuclide’s [Li et al., 2004] to 
the tumor.  
 One advantage of vascular targeting is the easy accessibility of the tumor 
endothelial cells. Targeting tumor vasculature with antibodies or immuno-conjugates is 
attractive because receptors and other target structures are readily available for binding 
directly in the blood stream [Oh et la., 2004; Simberg et al., 2007]. The direct access to 
the target skips the extravasation step from the blood into the tumor parenchyma [Oh et
al., 2004]. In addition, accumulation of antibodies at the endothelium is fast compared to 
accumulation in the solid tumor parenchyma [Burrows et al., 1992]. Kennel et al.,
showed that the maximal level of IgG accumulation in solid tumors was reached after 7 
days [Kennel, et al., 1991], whereas a saturation of endothelial binding sites at the tumor 
endothelium could be seen after 1 hour [Burrows et al., 1992; Kennel, et al., 1991]. It 
might therefore be easier and quicker to achieve accumulation of antibodies or immuno-
conjugates at the tumor vasculature as compared to tumor cells.   
In normal tissues, there are usually 1 or 2 layers of cells surrounding an individual 
vessel; in muscle tissue several capillaries supply one muscle fiber. The vessel network is 
highly organized and responds well to extra demands during stress [Denekamp, 1999]. In 
contrast, in tumor tissues one vessel supplies many hundreds or even thousands of tumor 
cells (Fig. 2). Untreated tumors show viable cells lying in a cuff around open vessels 
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cuffs are however surrounded by foci of necrosis [Kerbel and Folkman, 2002]. The 
destruction of one vessel therefore results in massive tumor cell death [Burrows and 
Thorpe, 1994; Denekamp, 1999], thereby amplifying the initial response.  
Figure 2. Tumor cells within 110 µm of a microvessel are viable (dashed line). Outside of this radius, 
tumor cells are dead [Kerbel and Folkman, 2002]. 
During the transformation from normal cell to neoplastic cells, tumor cells undergo 
multiple genetic changes [Hoffmann, 1990], which enables the tumors to quickly adapt to 
hostile environments by generating a new subpopulation. The plasticity of the tumor cell 
genome induces the development of resistance to therapies which are aimed directly at 
the tumor cell population [Kerbel, 1991]; in contrast, the tumor endothelial cells are 
genetically stable and therefore less likely to acquire mutations and develop drug 
resistance [Kerbel, 1991; Boehm et al., 1997; Kerbel and Folkman, 2002]. 
Tumor endothelial cells have a relatively high proliferation due to the tumor cell 
production of pro-angiogenetic cytokines, such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF), transforming growth factor ȕ (TGF-E)
and various interleukins [Kerbel and Folkman, 2002]. The pro-angiogenetic state results 
in the expression of surface antigens that are not expressed by normal endothelium 
[Burrows and Thorpe, 1994]. The similarities in tumor vasculature and behavior between 
various tumors make it possible to target the same tumor endothelial antigen in a broad 
10 
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variety of solid tumors [Denekamp, 1990; Lee et al., 2007]. In contrast to when targeting 
tumor cells, a single antibody could have a broad applicability. Furthermore, tumor 
endothelial cells express several proteins, including adhesion molecules, such as vascular 
cell adhesion molecule 1(VCAM), E-selectin and endoglin [Burrows and Thorpe, 1994], 
Į-intergrins [Arap et al., 1998; Lee et al., 2007] and receptors for certain angiogenic 
growth factors [Arap et al., 1998; Bazan-Peregrino et al., 2007], or stromal components 
[Simberg et al., 2007], which are not expressed by normal endothelium and can therefore 
be used to specifically target tumor vasculature. 
The development of a drug delivery system that specifically targets tumor 
endothelium has many advantages; one such delivery system could be liposomes.    
1.2 Immunoliposomes as a drug delivery system 
 Liposomes are nanoscale biocompatible drug carriers which can accommodate 
large amounts of both hydrophilic and lipophilic drugs entrapped in the aqueous core or 
the lipid bilayer, respectively [New, 1990; Sharma and Sharma, 1997]. Liposomes have 
been used as delivery systems for a broad spectrum of drugs including chemotherapy, 
imaging agents, antigens, lipids and nucleic acids [Marty et al., 2002].
Plain liposomes are made of phospholipids and sometimes cholesterol [Torchilin, 
1994]. When these liposomes are introduced into circulation, they are rapidly sequestered 
by macrophages of the reticuloendothelial system (RES) mainly located in the liver and 
spleen [Papahadjopouls et al., 1991]. Thus, they display a short blood half-life (min) and 
have a limited use as drug delivery carriers for transporting drugs to other sites than the 
RES. This led to the development of long-circulating liposomes, where specific 
amphiphiles, such as polyethylene glycol (PEG)-coupled phospholipids [Lasic et al.,
1991], the ganglioside GM1 [Allen and Chonn, 1987; Gabizon and Papahadjopoulos, 
1992] or hydrogenated phosphatidylinositol [Gabizon and Papahadjopoulos, 1992], were 
incorporated into the lipid membrane. This created a sterical stabilisation, which to 
increased liposome stability and blood half-lives required to ensure targeted delivery of 
the liposome to the right place of action [Allen et al., 1995]. PEG turned out to be the 
most applicable to sterically stabilise liposomes and other nano-carriers, because it is easy 
to prepare, its molecular weight is easy to control, it links easily to lipids and increases 
circulation time most effectively [Maruyama et al., 1995].   
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Figure 3. Immunoliposomes - (A1) antibodies attached to the surface of conventional liposomes; (A2)
antibodies attached to the surface of sterically stabilized liposomes (B) antibodies attached to the distal ends 
of polyoxyethylene chains in sterically stabilized liposomes. [Modified from 
www.pjonline.com/.../education/parenteral.html]
The coupling of antibodies or antibody fragments to the surface of liposomes for site-
specific targeting results in immunoliposomes (ILs) (Fig. 3) [Kontermann, 2006]. Three 
different types of ILs have been investigated. Type A1 where the antibody is conjugated 
to the lipids of the lipid bilayer, type A2 where the antibody is conjugated to the lipid 
bilayer on the surface of a PEG-liposome and type B where the antibody is conjugated to 
the distal end of the PEG chain [Maruyama et al., 1995]. Type A1 liposomes are, like 
conventional liposomes, cleared rapidly from circulation by RES, which reduces the 
targetability of the liposome [Torchilin, 1994; Hansen et al., 1995]. Type A2 liposomes 
attain longer circulation time because of the PEG, but encounter problems with binding to 
the target site. This is due to the steric barrier created by PEG [Klibanov et al., 1991]. 
Type B ILs have the advantage over type A1 and type A2 in that they bind to their binding 
site efficiently, because the antibody is presented on the tip of the PEG [Blume et al.,
1993; Maruyama et al., 1995]; and at the same time they retain a long circulation time 
[Maruyama et al., 1995]. 
1.2.1 Liposome distribution in vivo 
 The process of targeted drug delivery can be divided into two phases after 
administration [Mastrobattista et al., 1999]. The transport phase, where liposomes travel 
to the target cells, and the effector phase, where the liposomes are taken up by cells or 
12 
deliver the drug at the target site. During the transport phase the liposomes encounter 
various problems that are discussed below. 
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especially to the liver and spleen, has been 
leen, remove foreign 
particle
y with a Fc-
domain
y coupled to the liposome. Allen et al. showed that a high antibody density (140 
/µm
as et al., 2003] and that repeated 
administration of ILs results in drastically decreased circulation times. Antibody titers 
The biodistribution of systemically administered liposomes has been studied extensively, 
and unspecific localization of liposomes, 
observed [Proffitt et al., 1983; Dams et al., 2000; Bendas et al., 2003]. Elimination of 
liposomes through the RES [Gabizon and Papahadjopoulos, 1988] presents a problem, 
since it reduces the effective bioavailability of administered drugs. 
The removal of foreign particles in RES is part of a host defense mechanism, 
where macrophages in various tissues, such as the liver and sp
s from the circulation [Oku and Namba, 1994]. Plasma proteins and components 
play an important role in RES-mediated clearance as it has been shown that liposomes in 
media without blood components are not taken up by the liver [Semple et al., 1998]. 
Liposome uptake is believed to involve opsonic and scavenger receptors. Opsonins bind 
to the surface of liposomes and tag them so that they are recognized and engulfed by 
macrophages of the RES [Semple et al., 1998; Ishida et al., 2002]. The rate of clearance 
and opsonization is dependent on lipid composition, particle size and surface 
hydrophilicity [Allen and Chonn, 1987; Gabizon and Papahadjopoulos, 1992]. Thus small 
liposomes with a rigid membrane and incorporated PEG are removed slower from 
circulation by opsonization and RES [Gabizon and Papahadjopoulos, 1988]. 
There are other clearance problems specific for immunoliposomes. The clearance 
of immunoliposomes is enhanced when the target moiety is a whole antibod
. This makes the immunoliposome susceptible to Fc-mediated phagocytosis by Fc-
receptor expressing cells from RES [Aragnol and Leserman, 1986; Mastrobattista et al.,
1999]. Instead of using whole antibodies, several investigators have suggested the use of 
Fab’ [Maruyama et al., 1997], scFv [Xu et al., 2002; Völkel et al., 2004; Mamot et al.,
2005] or peptides [Kondo et al., 2004; Simberg et al., 2007], which could reduce the 
interaction with the RES and thereby prolong circulation time [Shahinian and Silvius, 
1995].
  Another factor that influences immunoliposomal clearance is the amount of 
antibod
µg ol lipid) increased the plasma clearance of IL as compared to moderate antibody 
densities (20-80 µg/µmol lipid) [ Allen et al., 1995]. 
Antibodies on the liposomal surface have been shown to induce an immune response 
[Phillips et al., 1994; Harding et al., 1997; Bend
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ere are also forces that enhance the 
accumu
The advantages of targeting the tumor endothelium and using ILs instead of 
immuno-conjugates as a drug delivery system have been combined in the development of 
itro studies report on targeting endothelial cells 
with IL
against ILs were elevated in individuals compared to those injected repeatedly with free 
antibody or PEG-liposomes and antibody separately [Harding et al., 1997]. Thus, it seems 
that it is the administration of the whole immunoliposomal complex that induces the 
immune response [Phillips et al., 1995]. Bendas et al. investigated the influence of the 
grafted position of the antibody (i.e. type A2 vs. type B) on the immunogenicity and found 
that ILs with antibodies on the tips of the PEG chains exhibited sufficient circulation 
time, also after repeated injections [Bendas et al., 2003]. It was suggested that the 
coupling method has an important impact on the immunogenicity and should therefore be 
determined for individual liposome preparations. 
The binding of antibodies to the surface of liposomes and the macrophages of the 
RES are factors that reduce the circulation time thereby preventing the liposome from 
reaching its target in the tumor. However, th
lation of liposomes in solid tumors. These forces are the result of the enhanced 
vascular permeability of the endothelial barrier and the lack of lymphatics in tumors, and 
are termed “the enhanced permeability and retention (EPR) effect” [Matsumura and 
Maeda, 1986; Maeda et al., 2004]. As previously mentioned, it has been shown that 
macromolecules, such as albumin, poly-(styrene-co-maleic acid half-n-butylate),
conjugated neocarzinostatin [Matsumura and Maeda, 1986], proteins and liposomes 
[Kirpotin et al., 2006], exhibit an enhanced accumulation in solid tumors [Noguchi et al.,
1998]. EPR is responsible for the passive accumulation of non-targeted sterically 
stabilized liposomes in the tumor, and the reason why non-targeted and targeted 
liposomes targeting the tumor endothelium or cells accumulate in the tumor to the same 
degree [Kirpotin et al., 2006]. Therefore, it is essential to determine the exact localization 
of the targeted liposomes when evaluating whether the ILs target successfully.  
1.2.2 Vascular-targeted liposomes 
vascular targeted liposomes. Several in v
s in an effort to ultimately place liposomes at sites of inflammation or tumor 
vasculature. The targeted receptors in those studies include endoglin [Volkel et al., 2004], 
vascular endothelial growth factor receptor 2 [Benzinger et al., 2000], galectin-1 
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 the Fc-receptor containing cells [Maruyama et al., 1997] and properly also 
reducin
[Brandwijk et al., 2007] intercellular adhesion molecule 1 [Bloemen et al., 1995] E-
selectin [ Spragg et al., 1997; Kessner et al., 2001 ], P-selectin [Scott et al., 2006] and 
VCAM [Chiu et al., 2003; Voinea et al., 2005, Gosk et al., 2005]. In vivo, ILs can be 
made to target inflamed vasculature [Everts et al., 2003] or vessels in areas of myocardial 
infarction [Nallamothu et al., 2006; Scott et al., 2006]. Several in vivo studies have 
investigated the tumor vascular targetability of liposomes decorated with peptides. These 
peptides include RGD motifs binding to Įvȕ3 integrins [reviewed in Temming et al.,
2005; Nallamothu et al., 2006; Lee et al., 2007], NGR motifs binding to aminopeptidase 
N [Pastorino et al., 2006], CREKA binding to fibrinogen or fibrin [Simberg et al., 2007], 
GPLPLR binding to membrane type-1 matrix metalloproteinase [Kondo et al., 2004], 
peptides binding to unknown receptors such as APRPG [Maeda et al., 2004], and the 
synthetic angiostatic peptide aniginex binding to galectin-1 [Brandwijk et al., 2007], 
which is a carbohydrate-binding protein with affinity for ß-galactosidase [Camby et al.,
2006].
Much research is being carried out with liposomes coupled to peptides. Peptides, 
instead of antibodies, have the advantage of a lesser clearance from the circulation by 
escaping
g the immunogenic response. Conceptually, peptides should also be superior to 
antibodies when aiming at targeting a compartment. Their small size and generally lower 
affinity potentially facilitates penetration into the tumor tissue. Furthermore, the generally 
lower binding affinity of peptides compared to antibodies can be of advantage when 
targeting the tumor cell compartment [Maeda et al., 2004], by escaping the binding site 
barrier. In contrast, high affinity binding would be preferable for robust tumor vascular
targeting, since ligands that bind to the luminal side of blood vessels are exposed to the 
dynamic flow environment of the blood stream. It is generally believed that most 
antibodies possess higher affinity binding properties than peptides. For example, to block 
the VCAM mediated leukocyte-endothelium interaction, a VCAM-binding peptide was 
applied at a 650-fold higher molar concentration than a VCAM-binding antibody to 
obtain similar degrees of inhibition [Kelly et al., 2005].  
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1.2.3 VCAM as a target on the tumor endothelium 
As mentioned earlier the tumor vasculature expresses molecules that are not 
present on normal endothelium. In the development of a vascular targeting drug delivery 
system it is important to choose a target, which ensures specificity and is widely 
applicable. VCAM was chosen for the work described here. 
VCAM is an immunoglobulin-like transmembrane glycoprotein of 110 KDa (Fig. 
4) expressed on activated endothelial cells during inflammation and cancer [Osborn et al.,
1989].
Figure 4. Protein structure of VCAM. VCAM-1 has 6-7 immunoglobulin-like domains [Kobayashi et al.,
2007].  
VCAM, also known as CD106, is a molecule with a well-characterized role in the 
immune system where it promotes firm cell-cell adhesion between migrating leukocytes 
and activated endothelial cells (Fig. 5). The mechanism of leukocyte migration to sites of 
inflammation is well characterized. Briefly, the cells interact in a sequential manner, 
where different types of adhesion molecules play different roles. First, the circulating 
leukocytes bind to selectins on the activated endothelium; this induces the leukocytes to 
roll along the endothelium. Following the rolling movement, other cell adhesion 
molecules of the integrin family that interact with members of the Ig-superfamily, such as 
VCAM or ICAM-1, mediate firm adhesion of leukocytes to the activated endothelium. 
16 
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Subsequently, this leads to the transendothelial migration of the leukocytes [Kobayashi et
al., 2007].
VCAM is an endothelial ligand for both integrins, very late antigen 4 (VLA-4) 
and Į4E7 [Wu et al., 2007], where VLA-4 is the most common receptor [Charpin et al.,
1998]. VLA-4 is expressed on inflammatory leukocytes, on some tumor cells and also on 
tumor endothelial cells. Besides their role in promoting cell-cell contacts between 
leukocytes and inflamed endothelium [Rice et al., 1990], the VCAM-VLA-4 interactions 
mediate binding of VCAM-positive pericytes and tumor endothelium [Garmy-Susini et
al., 2005], pro-angiogenic macrophages and tumor endothelium [Jin et al., 2006], or 
metastatic tumor cells and tumor vasculature [Klemke et al., 2007]. Therefore, VCAM 
plays an important role in tumor angiogenesis and metastasis.  
Figure 5. Leukocytes or cancer cells interact in a sequential fashion with adhesion molecules on vascular 
endothelium; 1) Rolling along the endothelial surface; 2) Firm adhesion to endothelium; 3) Extravasation of 
leukocytes or cancer cells to targeted tissue [Kobayashi et al., 2007]. 
If VCAM is to be considered a potential target structure in the tumor vasculature, VCAM 
expression needs to exhibit some degree of tumor vasculature specificity. VCAM 
expression is inducible and virtually absent in normal human vasculature [Kuzu et al.,
1993]. Its expression is induced by pro-inflammatory cytokines such as tumor necrosis 
factor Į (TNF-Į), interleukin 1E (IL-1E) [Wuthrich, 1994], IL-4 and interferon-J (INF-J ) 
[Wu et al., 2007]. Non-vascular cells with VCAM expression include bone marrow cells, 
17 
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follicular dendritic cells, fibroblasts, and epithelial cells in the kidney [Ryan et al., 1991; 
Seron et al., 1991]. However, the expression of VCAM outside the vasculature does not 
pose a major problem when targeting VCAM on tumor vascular, as the targeted 
liposomes will not come into contact with the other cells.  
Several diseases are associated with VCAM expression on the vascular 
endothelium, such as atherosclerosis, inflammatory diseases and autoimmune diseases 
[Dedrick et al., 2003]. In cancer, robust vascular VCAM expression has been observed in 
leukemias and lymphomas, such as Hodgkin’s disease and B-cell chronic lymphatic 
leukemia, and to varying degree in a variety of solid tumors such as lung cancer, breast 
cancer, melanoma, renal cell carcinoma, gastric cancer and nephroblastoma [reviewed in 
Dienst et al., 2005]. The expression of VCAM on various solid tumors makes VCAM an 
ideal target on the tumor endothelium. 
The fate of VCAM upon binding to its ligand is controversial. One study showed 
that after ligand binding, VCAM was internalized via a clatrin-dependent pathway with a 
half-life of 15 minutes in human umbilical vein-derived endothelial cells (HUVEC) 
[Ricard et al., 1998]. Another study found that VCAM remained mostly on the surface of 
the activated HUVEC [Kuijpers et al., 1994], whereas other studies suggest that parts of 
VCAM are shedded from the endothelial surface. The fate of VCAM after ligand binding 
needs still to be investigated. 
An alternative to creating an immunoliposomal system that targets the tumor cells 
would be the development of a liposomal drug delivery system that targets the VCAM at 
the tumor endothelium. The development of vascular acting anti-tumor drugs is being 
studied extensively. They could be used alone or in concert with conventional 
chemotherapy.  
 1.3 Vascular targeting drugs 
As described above, targeting tumor vasculature has many advantages. The use of 
conventional chemotherapy to kill tumor endothelium has been investigated. Two 
approaches have been tried; changing the treatment schedule [Hanahan et al., 2000; 
Miller et al., 2001] and targeting conventional cytotoxic anticancer drugs to the tumor 
endothelium using i.e. liposomes [Maeda et al., 2004; Pastorino et al., 2003; 2006; Lee et
al., 2007]. Conventional anticancer drugs are known to have an anti-angiogenic effect in
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vitro and in vivo [Miller et al., 2001]. The administration of low doses of conventional 
chemotherapy at constant intervals without resting periods can kill the tumor vasculature 
and at the same time exhibit low host toxicity [Browder et al., 2000; Hanahan et al.,
2000].
Apart from conventional therapy, two novel classes of drugs have emerged. They 
primarily target the tumor endothelial cells and exhibit an alternative molecular action. 
One approach targets key factors required for the formation of new vessels: anti-
angiogenesis agents [Kerbel, 2001; Siemann et al., 2005], who inhibit angiogenesis and 
are thought to normalize the vascular function by reestablishing the balance between the 
pro- and anti-angiogenesis factors [Jain, 2005]. Some angiogenesis inhibitors have been 
clinically approved. One example is Bevacizumab, a humanized monoclonal antibody 
targeting VEGF. Bevacizumab has shown clinical effects on colorectal cancer, breast 
cancer and non-small cell lung cancer in combination with cytotoxic chemotherapy 
[Hurwitz et al., 2004; Ramaswamy et al., 2006; Sandler et al., 2006]. Furthermore, it is 
used as a single agent in the treatment of metastatic renal cell carcinoma [Hinnen and 
Eskens, 2007].
  The second approach takes advantage of the differences between blood vessels in 
normal tissue and those of the tumor vasculature by targeting and destroying the existing 
tumor vasculature. These agents are called vascular disrupting agents (VDA) [Dienst et
al., 2005; Siemann et al., 2004].
VDAs destroy the tumors by inducing occlusion of the tumor vasculature. 
Occlusion leads to tumor cell starvation due to the lack of oxygen and nutrients [Thorpe, 
2004] which in turn leads to widespread necrosis in the tumor. VDAs are distinguished 
from anti-angiogenic drugs by targeting existing vessels which makes them well suited in 
the treatment of large bulky tumors (Fig. 6) [Siemann et al., 2004; Thorpe, 2004]. 
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Figure 6. Proposed principle of action of vascular-disrupting agents. A single vessel provides nutritional 
support to large numbers of tumor cells. Treatment with a vascular-disrupting agent induces endothelial cell 
dysfunction, which leads to partial occlusion of the vessel. The resulting diminished blood flow causes 
tumor cells farthest from the vessel to become increasingly hypoxic. As damage to the endothelium 
progresses, coagulation events are initiated, and blockage of the vessel ultimately occurs. This loss of vessel 
patency results in widespread tumor cell necrosis. [From Siemann et al., 2005]  
VDAs can be divided into two types; the ligand-directed VDAs and the small 
molecule VDAs. The ligand-directed VDAs use targeting ligands that specifically bind to 
structures on tumor endothelium and thereafter induce occlusion of the tumor vessel 
[Huang et al., 1997; Ran et al., 1998; Chiu et al., 2003; Dienst et al., 2005]. The small 
molecule VDAs exploit the pathophysiological differences between tumor and normal 
vasculature, i.e. increased proliferation, permeability and a reduced reliance on the 
tubulin cytoskeleton to maintain cell shape [Denekamp, 1990; Thorpe, 2004]. 
However, treatment with VDAs does not lead to complete tumor regression, but 
leaves a ring of viable tumor cells in the tumor periphery [Pastorino et al., 2003; Huang et
al., 1997]. These tumor cells obtain oxygen and nutrition from normal tissue vessels that 
are not targeted by the VDAs and therefore exhibit a good oxygen status resulting in 
tumor cells that are susceptible to conventional therapies, i.e. radiation or chemotherapies, 
which are most effective on well-oxygenated cells [Siemann et al., 2004; Horsman and 
Siemann, 2006].  
1.3.1 Ligand-directed VDAs 
 Several approaches based on linking antibodies or peptides that recognize tumor 
endothelium epitopes to effector molecules, that induce endothelial damage by selective 
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occlusion, have been investigated. The properties essential for the targeting moieties have 
been described above. The effector molecules exhibit a variety of activities including a 
direct or indirect induction of thrombosis. They redirect the host defense to attack the 
tumor, or change the morphology of the tumor endothelial cells to physically block the 
vessel [Thorpe, 2004]. The direct killing of endothelial cells by targeting toxins to the 
tumor was proven to be a successful approach. Several studies used chimeric fusion 
proteins with a toxin as the effector moiety targeted to the VEGF receptor. The effects of 
at least two different toxins, gelonin [Veenendaal et al., 2002] and diphtheria toxin [Arora 
et al., 1999], have been studied in vitro and in vivo. They induced thrombotic damage 
selectively at the tumor vessels and delayed tumor growth [Arora et al., 1999; 
Veenendaal et al., 2002]. Matsuno et al., targeted deglycosylated ricin A to the 
proliferation-associated antigen, endoglin, in mice bearing MCF-7 human breast cancer 
xenografts. This resulted in complete tumor regression [Matsuno et al., 1999].
 An alternative approach is to activate the host defense system by targeting 
inflammatory cytokines to the tumor vasculature. Targeting the tumor vasculature by 
creating a fusion protein in which the targeting part is the angiogenesis-associated 
isoform of fibronectin, ED-B, and the effector part being either IL-2 [Carnemolla et al.,
2002] or IL-12 [Halin et al., 2002] resulted in a significant, higher accumulation of tumor 
infiltrating T-lymphocytes, natural killer cells, macrophages and a delay in tumor growth 
time [Carnemolla et al., 2002; Halin et al., 2002]. However, the clinical application of 
cytokines is often hampered by severe systemic side effects.  
To avoid cytokine-induced side effects, ILs have been proposed as a delivery 
system in the development of ligand-directed VDAs. Liposomes have the advantage over 
immuno-conjugates in that they can encapsulate many effector molecules and therefore 
display a much higher ratio of effector molecules per targeting moiety [Marty et al.,
2002]. In addition, liposomes change the biodistribution and pharmacokinetics of drugs, 
thereby protecting the drug from metabolization and protecting the organism against the 
cytotoxic effects of the drug. The majority of studies on liposomal targeting of tumor 
vasculature have used liposomes encapsulated with conventional chemotherapeutics, such 
as doxorubicin [Volkel et al., 2004; Hölig et al., 2004; Pastorino et al., 2003, 2006; Lee et
al., 2007] or adriamycin [Maeda et al., 2004]. However, a few studies encapsulated a 
different class of drugs in the liposomes. Encapsulation of combretastatin A4, a small 
molecule VDA that induces depolymerisation of microtubules and disorganization of 
Introduction 
______________________________________________________________________________________ 
22 
actin and tubulin, was successful in vitro [Nallamothu et al., 2006]. Cationic liposomes 
were developed carrying a mutated form of the Raf gene, ATP
µ
-Raf, which blocks 
endothelial signaling and angiogenesis as a response to multiple growth factors. 
Treatment with these nano-particles resulted in endothelial apoptosis and regression of 
both primary and metastatic tumors [Hood et al., 2002]. In addition, vascular targeted 
liposomes with the stable isotope 
10
B were shown to reduce cell viability in vitro by 
neutron capture therapy [Koning et al., 2004]. 
1.3.2 Coagulation inducing VDAs 
1.3.2.1 Tissue factor as the effector in ligand-directed VDAs 
Another strategy that has proven successful is enhancing the pro-coagulative state 
of the tumor vasculature by directing truncated tissue factor (TF) to the tumor 
endothelium. Expression of TF at the tumor endothelium initiates the coagulation cascade 
leading to occlusion of the vessel. Truncated TF, consisting of the extracellular domain of 
the protein, has been investigated for anticancer treatment. The ability of truncated TF to 
induce coagulation is greatly reduced compared to full length TF [Philipp et al., 2003]. 
Free truncated TF in circulation does not induce clotting but becomes pro-coagulant when 
in contact with the endothelium [Thorpe, 2004]. One study describing the effect of 
truncated TF on tumor vasculature showed that free truncated TF alone did not have 
significant effects on tumor cell death. In contrast, when truncated TF was given in 
combination with low concentrations of bacterial lipopolysaccharide (LPS), which is an 
initiator of the immune system and coagulation system, a selective thrombosis of tumor 
vessels was found [Philipp et al., 2003]. This indicates that an additional pro-coagulative 
activation was essential for the non-targeted truncated TF to become fully active. 
Therefore, to increase the activity and localize the truncated TF directly to the tumor 
endothelium, several research groups created fusion proteins linking a targeting moiety to 
truncated TF.  
Tumor vessel markers such as MHC class II [Huang et al., 1997], VCAM [Ran et
al., 1998; Dienst et al., 2005], the ED-B domain of fibronectin [Nilsson et al., 2001], and 
prostate-specific membrane antigen [Liu et al., 2002] conjugated to truncated TF, induced 
intravascular thrombosis and tumor growth delay in various solid tumors in vivo [Thorpe, 
2004]. The hypothesis that an increase in TF concentration and activity at the tumor 
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endothelium could lead to tumor regression due to vessel occlusion was proven 
successful. However, inducing an up-regulation of native TF on the tumor vessels with 
cytokines or drugs could be an alternative to the treatment with truncated TF. 
1.3.2.2 TF and the coagulation cascade 
TF is a membrane-bound 47 kDa glycoprotein which plays an essential role in the 
initiation of extrinsic coagulation cascade in vivo (Fig. 7). The primary function of TF (in 
adults) is to initiate coagulation. This occurs when TF is exposed to coagulation factors in 
the bloodstream due to vascular injury. The extracellular domain of TF then becomes 
essential by binding to and acting as a cofactor for factor VII/ VIIa. The TF:VIIa complex 
acts as a serine protease converting factor IX and X to factor IXa and Xa, respectively, 
via limited proteolysis [Rehemtulla et al., 1991; Bogdanov et al., 2006]. The activated 
factor Xa together with its co-factor factor Va catalyses the conversion of prothrombin to 
thrombin. Thrombin cleaves fibrinogen to fibrin which together with platelets forms a 
stable clot (Fig. 7).   
The vast majority of factor VII is found as a zymogene in circulation and less than 
1 % is found as the activated factor VIIa. The conversion of factor VII in circulation is 
mediated by coagulation proteases, presumably primarily by factor XIa [Wildgoose et al.,
1992], but other factors such as factor IXa, Xa, XIIa, thrombin and plasmin have been 
shown to convert factor VII to factor VIIa in vitro [Morrissey, 2001]. TF can bind both 
the zymogene and the activated factor VIIa. The majority of factor VII is rapidly 
converted to its active state after binding to TF [Nemerson and Repke, 1985; Rao and 
Rapaport, 1988], and the TF:VIIa complex can catalyze the activation of factor VII in an 
auto-activation reaction [Morrissey, 2001].
The activity of coagulation proteins is strongly enhanced by binding to negatively 
charged membrane phospholipids, such as phosphatidylserine (PS). Therefore, free 
coagulation factors in the circulation display a negligible activity towards their respective 
substrates [Zwaal et al., 1998]. Under normal conditions PS is found in the inner leaflet of 
the membrane. However, upon cell injury or platelet activation it is translocated to the 
outer leaflet, thereby controlling the coagulation cascade under normal conditions. 
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Figure 7. Schematic illustration of the intrinsic (contact system) and extrinsic (cell injury) coagulation 
cascade. Tissue factor pathway: the main role of the tissue factor pathway is to generate a "thrombin burst". 
TF forms a complex with FVIIa (TF-FVIIa) which activates FIX and FX. FVII itself is activated by 
thrombin, FXIa, plasmin, FXII and FXa. The activation of FXa by TF-FVIIa is almost immediately 
inhibited by tissue factor pathway inhibitor (TFPI). FXa and its co-factor FVa form the prothombinase
complex, which activates prothrombin to thrombin. Thrombin then activates other components of the 
coagulation cascade, including FV and FVII (which activates FXI which in turn activates FIX), and 
activates and releases FVIII from being bound to vWF. FVIIIa is the co-factor of FXIa and together they 
form the "tenase" complex which activates FX and so the cycle continues. The contact activation pathway: 
formation of the primary complex on collagen by high molecular weight kininogen (HMWK), prekallikrein
and FXII (Hageman factor), prekallikrein is converted to kallikrein and FXII becomes FXIIa. FXIIa 
converts FXI into FXIa. FXI is also activated by FVIIa. Factor IX is in turn activated by FXIa which with 
its co-factor FVIIIa form the tenase complex which activates FX to FXa. Thrombin primary role is the 
conversion of fibrinogen to fibrin, the building block of a haemostatic plug. In addition, it activates Factors 
VIII and V and their inhibitor protein C (in the presence of thrombomodulin), and it activates Factor XIII, 
which forms covalent bonds that crosslink the fibrin polymers that form from activated monomers. 
http://www.biocrawler.com/encyclopedia/Image:Coagulation_cascade.png
The coagulation proteins that participate in the lipid-associated complexes can be 
divided into three categories. The first category includes factors VII, IX, X and protein C 
that have 9 to 12 J- carboxyglutamic acid residues in the N-terminal, which are involved 
in the Ca
2+
 dependent binding to negative phospholipids. These residues are created by 
postribosomal vitamin K-dependent carboxylation [Zwaal et al., 1998]. Secondly, non-
enzymatic co-factors, such as factor V and VIII, are Ca
2+
 dependent, and need proteolytic 
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activation to facilitate the enzyme-substrate reaction [Davie et al., 1991]. The last group 
contains TF, a member of the class 2 cytokine receptor super family and a type I integral 
protein. TF does not need proteolytic activation, but must be anchored to a membrane to 
fully support the proteolytic activity of factor VIIa [Morrissey, 2001].
1.3.2.3 Regulation of TF expression on endothelial cells 
The level of TF expression varies in the different organs. Brain, lung, heart, 
kidney, uterus, testis, skin and placenta express high levels, whereas organs such as the 
liver, spleen and skeletal muscle express only low levels of TF [Fleck et al., 1990]. Under 
normal conditions TF is not expressed on the surface of the endothelial cells, but by cells 
surrounding the vasculature that act as a protective haemostatic barrier upon disruption of 
the blood vessels. However, inflammatory mediators such as TNF-Į, IL-1E and LPS 
[Bevilacqua et al., 1986], and angiogenetic stimuli such as VEGF and TGF-E, have been 
shown to induce TF expression on endothelial cells, monocytes and fibroblasts [Osterud 
and Bjorklid, 2001; O’Reilly et al., 2003]. As a consequence, an inappropriate expression 
of TF is seen under various pathological conditions i.e. endotoxemia [Sharma et al.,
2004], atherosclerosis [Westrick et al., 2001] and in the development and progression of 
cancer [Yu et al., 2004].
VEGF is an important mediator of angiogenesis that activates endothelial cell 
survival, proliferation, migration and tube formation. VEGF also functions as a cytokine 
inducing the expression of different adhesion molecules (VCAM and integrins) and 
increasing endothelial permeability [Carmeliet, 2000]. Several studies have investigated 
the induction of TF on endothelial cells by VEGF alone or in synergy with TNF-Į. The 
biological effects of VEGF are mediated by its binding to the two tyrosine kinase 
receptors Flt-1 and KDR, where the latter has been shown to be the main receptor 
associated with endothelial cell proliferation, migration, vascular permeability, cell 
survival and angiogenesis [Shinaruk et al., 2003]. It has been suggested that KDR 
receptor signaling governs the VEGF-induced TF expression [Shen et al., 2000] through 
activation of the early growth response-1 (EGR-1) transcription factor [Mechtcheriakova 
et al., 2001].
TF expression is only slightly up-regulated by VEGF alone, but it is significantly 
enhanced when induced in synergy with TNF-Į [Clauss et al., 1996; Shen et al., 2001]. 
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TNF-Į is a potent pro-inflammatory cytokine, which originally was described as a 
mediator of hemorrhagic necrosis in murine tumors. Furthermore, TNF-Į affects the 
haemostatic properties of endothelial cells [Conway et al., 1989] through stimulation of 
two receptors in the cell membrane, the 60 kDa TNF-Į receptor (TNFR60) and the 80 
kDa TNFR (TNFR80). The principle receptor involved in the TNF- Į induced up-
regulation of TF is TNFR60 [Clauss et al., 1996].  
TF is classified as an immediate-early response gene, because its transcription is 
directly induced before de novo synthesis of other proteins [Mackmann, 1995]. TNF-Į
induced de novo synthesis of the TF protein in human microvascular dermal endothelial 
cells. Experiments blocking either the nuclear factor-NB (NF-NB) or p38 mitogen-
activated protein kinase partly blocked the expression of TF [O’Reilly et al., 2003], 
indicating that these two signaling pathways are involved in the TNF-Į induced TF 
expression in human microvascular dermal endothelial cells. In contrast, the expression of 
TF in porcine aortic endothelial cells after LPS treatment was the result of a concerted 
action mediated by transcription factor AP-1, NF-NB and Sp-1-like factors, which lead to 
transcription from the TF promoter [Moll et al., 1995]. It appears that different signaling 
pathways are involved in the induction of the TF protein, and the process might be both 
species and cell type specific.
In addition to the transcriptional control of TF activity, i.e. increasing its 
expression on the vasculature, it has been suggested that TF exists in an encrypted state 
on the surface of non-perturbed cells, and that encryption of TF may contribute to 
controlling its activity in coagulation. Previous studies have shown that some quiescent 
endothelial cells express TF on their surface, but exhibit limited TF activity. However, 
when detached with trypsin the TF activity was increased [Maynard et al., 1975]. This 
suggests the existence of a mechanism that maintains TF in a protected or encrypted state, 
and that stress or stimulation can induce decryption of TF. The mechanisms behind 
decrypting TF are now being investigated. One study found that an increase in cytosolic 
Ca
2+
 concentrations increased TF activity [Bach and Rifkin, 1990]. Other studies found 
that the presence of the anionic lipid, PS, increased TF activity, and that PS therefore 
might participate in the activation of TF [Bach and Rifkin, 1990; Pendurthi et al., 2007].
The TNF-Į induced expression and activation of TF is well documented. 
Therefore the use of TNF-Į to induce TF expression and clotting in the tumor vessels is 
an attractive strategy. In addition, solid tumors secrete VEGF due to their angiogenetic 
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state. Thus tumor-derived VEGF, together with targeted TNF-Į, can synergistically 
increase the TF expression on tumor endothelium. TNF-Į has previously been used in the 
treatment of solid tumors and being a pleotropic cytokine, it has multiple effects on the 
endothelium. The sum of these effects can induce vascular collapse.
1.3.3 TNF-Į; as a VDA 
 TNF-Į is a multifunctional cytokine that plays an important role in inflammation 
and immunity, as well as in the control of cell proliferation, differentiation and apoptosis. 
TNF-Į was isolated in 1975 from serum of mice treated with LPS as the active 
component of Coley’s toxin. It got its name from its ability to induce necrotic hemorrhage 
in murine solid tumors [Carswell et al., 1975; Wanatabe et al., 1988]. Currently, TNF-Į is 
used in anticancer treatment of soft tissue sarcoma, irresectable tumors of different 
histological origin and in-transit melanomas in the limbs by isolated limb perfusion [ten 
Hagen and Eggermont, 2004]. The antitumor effect induces vascular occlusion leading to 
tumor cell necrosis [Stoelcker et al., 2000; Friedl et al., 2002].
 TNF-Į is a 17 kDa protein that forms a homotrimer in solution. It is mainly 
produced by activated macrophages, T lymphocytes and natural killer cells, but other cell 
types such as fibroblasts, smooth muscle cells and tumor cells also produce low levels of 
TNF- Į [van Horssen et al., 2006]. TNF-Į is synthesized as the membrane bound pro-
TNF-Į, which is cleaved by the TNF-Į converting enzyme and released into the 
circulation [Bemelmans et al., 1996]. As mentioned above, TNF-Į exerts its action 
through two receptors. TNF-Į has highest affinity for TNFR80 but seems to exert most of 
its biological function through the TNFR60 (also called TNFR1), which is expressed on 
all cell types. TNFR80 is mainly expressed on cells of the immune system [Aggarwal et
al., 2003]. The two receptor have been shown to cooperate; at low TNF-Į concentrations 
TNFR80 seems to be involved in catching and passing the ligand on to the TNFR60 
[Clauss et al., 1996]. 
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Figure 8. Schematic overview of the signaling pathways initiated upon binding of TNF-Į and TNFR60 
trimerzation. The signaling pathways are reviewed in van Horssen et al (2006) [from van Horssen et al.,
2006] 
The main difference between the two receptors is the presence of the death 
domain (DD) on the TNFR60, but not on TNFR80. The DD therefore makes TNFR60 a 
member of the family of death receptors, which are apoptosis-inducing receptors [van 
Horssen et al., 2006]. Besides signaling apoptosis, the TNFR60 also signals cell survival 
and activation by inducing the expression of inflammatory proteins [Kuldo et al., 2005]. 
 When TNF-Į homotrimer binds to the TNFR60, the receptor trimerizes, causing 
the protein silencer of death domain (SODD) to be released. Thereafter the protein 
TNFR-associated death domain (TRADD) binds to the DD, which in turn recruits the 
adaptor proteins receptor interacting protein (RIP), TNFR associated factor 2 (TRAF-2) 
and Fas-associated death domain (FADD) [Aggarwal, 2003; van Horssen et al., 2006]. 
Here, the two signaling pathways split up depending on the outcome of the signaling. 
TNFR60 signals apoptosis when it recruits FADD which thereafter initiates the caspase 
cascade (Fig. 8). However, when it signals survival TRAF-2 is recruited to the complex. 
The binding of TRAF-2 inhibits apoptosis and induces phosphorylation and activation of 
more signaling pathways. This process results in the activation of the transcription factors 
cFos/cJun and NF-NB, where NF-NB constitutes the major signaling pathway [Devin et
28 
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al., 2000]. The effect that TNF-Į exerts is concentration-dependent. High concentrations 
induce the vascular-toxic pathway, whereas lower concentrations promote DNA and 
protein synthesis [van der Veen et al., 2000]. 
 As mentioned above, TNF-Į exerts many effects on endothelium. It can induce 
coagulation through up-regulation and activation of TF and it can permeabilize the 
endothelial barrier and induce vascular obstruction due to endothelial apoptosis. 
  The apoptotic effect of TNF-Į on endothelial cells has been investigated in 
HUVECs [Ramana et al., 2004; Carroll et al., 2004] and bovine pulmonary arterial 
endothelial cells [Polunovsky et al., 1994]. The inhibition of protein synthesis by treating 
the cells with either actinomycin D or cycloheximide attenuates the TNF-Į induced 
apoptosis [Polunovsky et al., 1994]. This could be due to the dual signaling of TNF-Į
where the cell upon TNFR60 activation up-regulates the pro-survival genes and renders 
the cells less sensitive to TNF-Į mediated apoptosis [Jimienez et al., 2003]. It has also 
been suggested that the production of reactive oxygen species (ROS) plays a role in TNF-
Į mediated cell death. TNF-Į increases the production of ROS, but the role of ROS in the 
apoptotic pathway is conflicting. When initiating the apoptotic pathway, TNF-Į also 
activates the anti-apoptotic pathway, including the transcription factor NF-NB [Ramana et
al., 2004]. NF-NB regulates genes that promote cell survival and their activation and 
might therefore rescue the cell from death. However, activation of NF-NB is redox-
sensitive, and it has been shown that ROS, as a secondary effect, inhibits NF-NB
activation [Ramana et al., 2004] thereby promoting apoptosis.  
 TNF-Į provokes the biosynthesis and release of multiple endogenous mediators 
that directly or indirectly influences the endothelial barrier function. Neumann et al.
showed that Evans blue labeled albumin was cleared from the pulmonary micro-vessel 
endothelial monolayer within 30 min of TNF-Į treatment [Neumann et al., 2006]. The 
increased permeability of the endothelial barrier is mediated through the activation of 
multiple protein tyrosine kinases [Angelini et al., 2006], which results in the down-
regulation of primary endothelial intracellular adhesion molecules, vascular endothelial-
cadherin, and in the contraction of F-actin cytoskeletal elements [Friedl et al., 2002].
 TNF-Į induces a pro-coagulative state, increased permeability and apoptosis in 
endothelial cells. Treatment with TNF-Į induces thrombosis and necrosis in mice bearing 
human xenograft tumors [Watanabe et al., 1988; Nawroth et al., 1988]. However as TNF-
Į is a multi-functional cytokine, systemic treatment with even the minimal clinical doses 
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is often hampered by severe side effects [Kim et al., 2002a], such as hypotension, fever, 
nausea, headache, and tachycardia. Therefore, TNF-Į is not applied in systemic treatment, 
but is given through isolated limb perfusion, often together with melphalan [Grunhagen et
al., 2006; Verhoef et al., 2007]. This technique allows for 10-fold higher doses of the 
systemic mean-tolerated dose of TNF-Į, with negligible systemic toxicity [Hayes et al.,
2006].
Treatment with low doses of TNF-Į is another way to circumvent the severe side 
effects. Low doses of TNF-Į in combination with liposomal doxorubicin (Doxil®)
produces a better tumor response in osteosarcoma-bearing rats [Hoving et al., 2005] and 
in B16BL6 melanoma xenograft-bearing mice [Seynhaeve et al., 2007] as compared to 
treatment with Doxil
®
 alone. Another study employed low doses of TNF-Į and liposomal 
cisplatin and found that the combination resulted in a prolonged anti-tumor activity in rats 
bearing soft-tissue sarcomas, but not in rats bearing ostesacroma [Hoving et al., 2005]. 
The effect of the combination treatments is thought to be due to an increased vascular 
permeability, increased tumor accumulation and a more homogenous drug distribution in 
the tumor [Seynhaeve et al., 2007]. However, the outcome might depend on the type of 
tumor [Hoving et al., 2005].  
 Apart from isolated limb perfusion and low levels of TNF-Į, investigators have 
tried to target TNF-Į specifically to the tumor. TNF-Į conjugated to the tumor cell 
antigen, carcinoembryonic antigen [Larbouret et al., 2007] and NGR-peptide [Corti and 
Ponzoni, 2004], exhibited anti-tumor activity and resulted in fewer side effects [Larbouret 
et al., 2007]. Another approach was to encapsulate TNF-Į in sterically stabilized 
liposomes [Kim et al., 2002a,b; Debs et al., 1990; ten Hagen et al., 2002; Morishige et
al., 1993]. Incorporation of TNF-Į into sterically stabilized liposomes has many 
advantages in systemic treatment. Liposomal TNF-Į exhibits a prolonged circulation 
time, accumulation in the tumor and decreased cytotoxicity [Debs et al., 1990; van der 
Veen et al., 2000; Kim et al., 2002a; ten Hagen et al., 2002].
The immunomodulatory and toxic effects of TNF-Į liposomes were initially 
investigated in rats. Liposomal TNF-Į exhibited the same immunomodulatory effects as 
free TNF-Į, but with fewer toxic side effects [Debs et al., 1990]. The anti-tumor effect of 
TNF-Į liposomes alone or in combination with other conventional anti-cancer treatments 
has also been studied. Treated mice bearing LS174T human colon cancer xenografts 
exhibited prolonged the recruitment and activation of leukocytes as compared to 
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treatment with free TNF-Į [Kim et al., 2002a]. When TNF-Į liposomes were given in 
combination with radiation, the inhibition of tumor growth was enhanced synergistically 
without the dose-limiting toxicities [Kim et al., 2001]. It was suggested that the reason for 
this was that TNF-Į liposomes resulted in a prolonged activation of the immune system 
[Kim et al., 2002a]. Moreover, the combination of liposomal TNF and liposomal 
doxorubicin (Doxil
®
) markedly augmented the antitumor activity, without increasing the 
toxic side effects seen in the combination of free TNF-Į and Doxil® [ten Hagen et al.,
2002]. Since the encapsulation of TNF- Į reduced the systemic side effects, TNF-Į
liposomes seems to be a promising alternative when using TNF-Į in anti-tumor treatment. 
It might even enhance the effects of TNF-Į on the tumor endothelium when targeting the 
liposomes directly to the tumor endothelium. 
1.3.4 DMXAA as a TNF-Į inducing small molecule VDA 
In an attempt to limit the TNF-Į induced side effects, a search for agents that 
stimulate the synthesis of TNF-Į in tumors was initiated. This led to the finding of 
flavone acetic acid (FAA), which by inducing TNF-Į synthesis, is a potent drug against 
solid tumors in mice. FAA showed regression of Colon 38 tumors in mice [Plowmann et 
al., 1986], but phase II trials showed that FAA had no effect on human tumors [Kerr and 
Kaye, 1989]. Derivatives of FAA were therefore synthesized, the most potent being 5,6-
dimethylxanthenone-4-acetic acid (DMXAA, Fig. 9) [Rewcastle et al., 1991].
Figure 9. The chemical structure of DMXAA. 
DMXAA’s activities in mice include induction of TNF-Į and INF-J [Joseph et al.,
1999], serotonin release [Baguley et al., 1997], increased vascular permeability [Chung et
al., 2007], tumor blood flow inhibition and induction of hemorrhagic necrosis and tumor 
regression (Fig. 10) [Zhao et al., 2002]. In contrast to FAA, DMXAA was shown to 
induce TNF-Į synthesis in both mouse and human cells in vitro [Philpott et al., 1997]. 
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DMXAA also induced a rapid vascular collapse in the tumors of mice transplanted with 
Colon 38 xenografts [Joseph et al., 1999]. As mentioned above, apart from TNF-Į,
DMXAA also induces other cytokines, such as interferons. To investigate whether the 
antitumor effects of DMXAA were dependent on the synthesis of TNF-Į and INF-J,
knock-out mice lacking their receptors were treated with DMXAA. Treatment of IFN-J
receptor knock-out mice bearing Colon 38 tumors with DMXAA resulted in 100% 
regression of the tumor, even though the required dose was higher and the reduction in 
tumor volume was slower. This suggested that IFN-J was not crucial for the anti-tumor 
response [Pang et al., 1998]. In order to evaluate the role of TNF-Į in the DMXAA 
induced anti-tumor response, TNF-Į receptor knock-out mice were compared to wild type 
mice with respect to the dose and curability. The TNF-Į knock-out mice showed a 
considerably higher maximum-tolerated dose when compared to wild type mice (>100 
mg/kg vs. 25mg/kg), and treatment with 50 mg/kg DMXAA resulted in a curative and 
comparable effect to wild type mice treated with 25 mg/kg DMXAA [Zhao et al., 2002]. 
Although TNF-Į plays an important role in the DMXAA-induced host toxicity and anti-
tumor effect, it can be replaced with a TNF-Į independent mechanism. Comparing the 
levels of TNF-Į induced by DMXAA and LPS in the tumor it was shown that DMXAA 
induced a larger amount of TNF-Į in tumors as compared to LPS [Joseph et al., 1999], 
indicating that the activity of DMXAA is more specifically located to the tumor and that 
DMXAA is a potent inducer of TNF-Į.
Figure 10. Schematic depiction of the direct and indirect activities of DMXAA.DMXAA exerts a direct 
effect on the endothelium where it induces apoptosis, but also indirect effects such as the synthesis of TNF-
Į and serotonin [Rosenthal and Pili, 2007]. 
32 
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Pre-clinically, DMXAA has been shown to target tumor vasculature and cause 
tumor regression, necrosis and a reduction in micro-vessel density in mice bearing head 
and neck squamous cell carcinomas [Seshadri et al., 2006] and Colon 38 tumors [Zhao et
al., 2002] and in rats bearing chemically induced primary mammary tumors [Liu et al.,
2007a]. DMXAA exhibits anti-tumor activity and reduction in tumor blood flow at well 
tolerated doses in clinical phase I trials [Jameson et al., 2003]. However, treatment with 
DMXAA alone, as with the other VDAs, does not lead to complete tumor regression. 
Currently, DMXAA is undergoing clinical phase II trials in combination with 
conventional anticancer drugs [McKeage, 2008]. One study is assessing the efficacy of a 
triple treatment with paclitaxel, carboplatin and DMXAA in patients with recurrent 
ovarian cancer. Preliminary data reveal that DMXAA does not add significantly to 
toxicity [Gabra, 2006]. No additional toxicity was found in patients with non-small cell 
lung cancer receiving the same triple treatment and initial data suggest that the 
combination has a beneficial effect compared to conventional treatment [McKeage, 
2008]. The combination of docetaxel and DMXAA for patients with hormone-refractory 
metastatic prostate cancer did not add to the toxicities and showed promising activity 
[Rosenthal and Pili, 2007]. These phase II trials are encouraging and support further 
development of DMXAA as an anticancer drug.
One problem with DMXAA is that it exhibits a steep dose curve in mice, resulting 
in a narrow therapeutic window. Treatment with 15 mg/kg has no anti-tumor effect, while 
a treatment with 30 mg/kg kills the mice [Murate et al., 2001]. Subsequently, employing a 
vascular targeted approach, with i.e. tumor endothelium targeted liposomes might 
broaden the therapeutic window by either making it possible to work with lower doses or 
by reducing the toxicity of higher doses.
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1.4 Aim of study  
The main goal of this project was to evaluate and develop a novel therapeutic 
principle for treating solid tumors by combining a non-cytostatic drug carrier targeted to 
the tumor vasculature and the occlusion and destruction of the tumor blood vessel system. 
Therefore, the project is divided into two parts; (i) a liposomal carrier system for specific 
targeting of the tumor vasculature had to be generated and evaluated under in vitro and in 
vivo conditions with respect to targetability, tumor specificity and the fate of the 
liposomes at the target site. (ii) The molecular mechanisms of TF expression by 
endothelial cells as a key for inducing blood coagulation had to be investigated. Potential 
inducers of TF expression were evaluated as possible agents for liposomal targeting and 
their anti-tumor activity was evaluated in a mouse tumor model. 
VCAM appears to be the most attractive target molecule on the endothelium for a 
liposomal targeting strategy; VCAM is not expressed on normal endothelium but is up-
regulated on tumor endothelial cells. Consequently, different VCAM-directed 
immunoliposomes were introduced and investigated. Special emphasis has been put on 
the vascular localization of these immunoliposomes vs. the unspecific uptake in the tumor 
tissue. As a novel approach, TNF-D and the TNF-Į inducing, DMXAA was encapsulated 
into targeted liposomes. This will protect the organism against potential systemic effects 
of TNF-D, and simultaneously, ensure selective delivery to the tumor endothelial cells. 
This should lead to an induction of TF expression and activity with a subsequent initiation 
of the coagulation cascade and ultimately, to occlusion of the tumor vessels and starvation 
of the tumor cells (Fig. 11). Hence, the strategy is to starve tumor cells by injuring 
existing tumor-feeding blood vessels by inducing occlusion of the vessel and stopping the 
flow of nutrients and oxygen to the tumor cells. This will lead to killing the cancer cells in 
the core of the tumor, which will make the peripheral parts of the tumor particularly 
amenable for adjuvant therapy with radiation or cytostatic treatment (cf. Horsman and 
Siemann, 2006). The aim of the thesis is schematically summarized in Fig. 11. 
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Coagulation 
TNF-Į
Figure 11. Illustration of intra-tumor blood coagulation induced by the release of TNF-D from vascular-
targeted liposomes conjugated with anti-VCAM antibodies. 
    = TNF-loaded liposomes coated with anti-VCAM antibodies target VCAM-   
       expressing endothelial cells of the tumor. 
Starved tumor cells
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2. Material and Methods 
2.1. Reagents
Reagents were obtained from the following sources: soy phosphatidylcholine 
(SPC) was kindly donated by Lipoid AG Ludwigshafen (Germany), polyethylenglycol 
(2000)-phosphatidylethanolamine (PEG-PE), Lissamine
®
Rhodamine-B-DPPE, N-
glutaryl-PE (Ng-PE) were purchased from Avanti Polar Lipids (Alabaster, USA). 
Cyanuric chloride, cholesterol (Chol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid 
(EDC), N,N diisopropylethylamin, 3,3´- Dioctadecyloxacarbocyanine perchlorate (DiO) 
and recombinant murine TNF-D were from Sigma-Aldrich (Deisenhofen, Germany). 
DMXAA was a kind gift from M. Horseman, (Århus University, Denmark).  
The antibodies were as follows: rat anti-mouse VCAM (clone MK271, rat anti-mouse 
CD31 (clone 390) and rat anti-mouse Meca32 antigen (clone Meca32) were purified from 
hybridoma cell supernatant (see section 2.2) using rat anti-mouse-IgG-agarose affinity 
columns (resin from Sigma-Aldrich); isotype-matched rat control antibodies (IgG1) and 
anti-CD11b (clone OX 42) were obtained from BD Pharmingen (Heidelberg, Germany); 
fractionated human IgG with irrelevant specificity and FITC-conjugated goat anti-rat 
secondary antibody came from Sigma-Aldrich; anti-macrophage BM8 antibody, 
recognizing the F4/80 maturation antigen, came from Dianova (Hannover, Germany), 
Alexa Fluor
®
 568 conjugated goat anti-rat secondary antibody and goat anti-mouse came 
from Molecular Probes (Invitrogen, Karlsruhe, Germany). Rabbit anti-mouse tissue factor 
from immunized rabbit was a kind gift from C. Gottstein (Santa Barbara, USA). Goat 
anti-rabbit IgG conjugated to horseradish peroxidase was obtained from BD Pharmingen 
(Heidelberg, Germany) and FITC-conjugated goat anti-rabbit IgG was from Sigma-
Aldrich (Deisenhofen, Germany). 
Octyl-ß-D glucopyranoside was obtained from Alexis (Grünberg, Germany). The 
salts used to prepare the buffers (PBS, TRIS, HEPES, Borat-buffer, Lysis-buffer) were all 
analytical grade salts from Fluka (Neu-Ulm, Germany). The detergents Triton-X-100 and 
sodiumdeoxycholate, the chromogenic horseradish peroxidase substrate 3, 3’, 5, 5’-
tetramethyl benzidine (TMB), fluorescence mounting buffer, paraformaldehyde, 65 mM 
phosphate standard, Folin-Ciocalteau reagent were obtained from Sigma-Aldrich 
(Deisenhofen, Germany). The TNF-Į ELISA kit was obtained from Endogen (USA) and 
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the in situ Apoptag® TUNEL assay kit was from Chemicon (CA, USA). NuPage® 
Western Blot kit was obtained from Invitrogen (Karlsruhe, Germany). 
2.2. Cell lines 
Hybridoma cell line MK271 was from ATCC, Manassas, VA, USA; hybridoma 
cell line 390 was from S. Albelda, University of Pennsylvania, Philadelphia, PA, USA; 
hybridoma cell line Meca32 was from E. Butcher, Stanford University, Stanford, CA, 
USA. The murine brain endothelium cells, bEnd3, were obtained from B. Engelhardt, 
Theodor Kocher Institute, University of Bern, Switzerland. A2780, a human ovarian 
cancer cell line, was obtained from M. Wiese, Pharmaceutical Department, University of 
Bonn. Human tumor cell line Colo677, originally described as non-small cell lung cancer 
cell line, is a myeloma cell line from DSMZ, Braunschweig, Germany, which forms solid 
tumors with VCAM-positive vessels after subcutaneous injection [Dienst et al., 2005]. 
B16F10 are murine melanoma cells, which express tissue factor constitutively, came from 
R. Ludwig, University Clinic Frankfurt. All cell lines except bEnd3 and B16F10 were 
cultured in RPMI 1640 medium supplemented with 10 % fetal calf serum (FCS), 100U 
penicillin and 100 µg streptomycin at 37qC in a 5% CO2 incubator. The bEnd3 and 
B16F10 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10 % FCS, 100U penicillin, 100µg streptomycin and 4mM glutamine. 
All cell culture reagents were obtained from Sigma-Aldrich (Deisenhofen, Germany).  
2.3 Synthesis of the cyanur-PEG-PE anchor 
The synthesis of the cyanur-PEG-PE anchor was performed as previously 
described by Bendas et al. [1999], in one step. Briefly, 50 mg DSPE-PEG2000-NH2 was 
dissolved in 18 ml chloroform, after which 5 mg cyanuric chloride and 2.5 mg N,N 
diisopropylethylamin were added. The reaction was allowed to run to the end for 72 hours 
under constant agitation at room temperature. The reaction product was checked using 
thin layer chromatography (TLC). A silicate TLC plate (Merck, Germany) was used. 2-5 
µl of reaction solution was applied to the TLC plate. Furthermore, to identify the lipid 
spots, standards consisting of cyanuric chloride and DSPE-PEG-NH2 were also applied. 
The lipids were eluted with chloroform: methanol: NH3 (65:35:1 v/v/v) and visualized 
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with UV and molybdenum blue reaction [Dittmer and Lester, 1964] (solution 1: 4.011 g 
MoO3, 100 ml H2SO4 boiled for 3-4 hours and cooled down overnight; solution 2: 0.178 g 
molybdenum, 50 ml solution boiled for15 min; spray reagent: equal volumes of solution 1 
and 2 to 4.5 volume parts H2O). The reaction mixture was washed twice with methanol 
and after evaporation the Cyanur-PEG-PE was dissolved in chloroform to a concentration 
of 1 µmol/ml.  
2.4. Liposome preparation
The liposomes used in this work, regardless of the different labels (fluorescence or 
radioactive) and different encapsulated drugs (TNF-Į and DMXAA), were all prepared 
with the hydration method.  
2.4.1 Preparation of empty liposomes 
Liposomes were prepared from SPC/cholesterol/mPEG2000-PE/anchor/DiO in a 
ratio of 60/30/5/5/0.5 mol % and hydrated with a 0.9 % NaCl solution to a final lipid 
concentration of 30 mM. In some preparations, trace amounts of [
3
H]-
cholesteryloleylether (Amersham, Buckinghamshire, U.K.) (0.25 µCi/µmol lipid) were 
added instead of the DiO label. To couple a protein to the liposomal surface, two different 
coupling-anchors were used; either the NgPE anchor or the cyanur-PEG2000-PE anchor, 
which couples the targeting device directly to the surface of the liposomes or to the 
terminal ends of the PEG chain, respectively [Bendas et al., 1999]. When preparing 
liposomes with the cyanur-anchor the mPEG2000-PE was omitted.  
Unilamellar liposomes were prepared with a Mini-extruder (Avanti Polar Lipids, 
Alabaster, USA) from multilamellar vesicles extruded 19 times through a 200 nm 
polycarbonate membrane, 19 times through a 100 nm polycarbonate membrane and 10 
times through a 50 nm polycarbonate membrane (Whatman Nuclepore 18 mm 
polycarbonate membrane, Richmond, USA).  
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2.4.2 Preparation of TNF-Į and DMXAA liposomes 
2.4.2.1 FITC-labeling of TNF-Į
1 mg TNF-Į was dissolved in 1ml 0.9% NaCl solution. Before labeling, the buffer 
was replaced with a carbonate/bicarbonate buffer pH 8.8 using a Biospin 6 column 
(BioRad Laboratories, München, Germany). The amount of fluorescein isothiocyanate 
(FITC) labeling reagent (Pierce, Il, USA) to be added was calculated by using a 24-fold 
molar excess of the fluorescent dye to protein according to the manufacturere’s 
recommendation. The FITC salt was dissolved in carbonate/bicarbonate buffer and added 
to the TNF-Į, vortexed thoroughly and incubated for 1 hour at room temperature in the 
dark. Thereafter, excess FITC was removed by gel filtration using a BioSpin 6 column 
(cut-off: 6000 Da). The concentration and the degree of labelling were determined by 
measuring the absorbance at 280 nm and at the dye’s maximum wavelength (494 nm for 
FITC, A494). Thereafter equation 1 was used. 
Protein concentration (M) = (A280 – (A494 x Correction factor))/H  (1) 
where A280 gives the protein concentration in the sample and the correction factor is used 
to correct for the absorbance of the fluorescence dye at 280 nm. H is the molar extinction 
coefficient of the labeled protein (TNF-D, 17500) and A494 the absorbance at the dye’s 
maximum wavelength. 
The degree of labelling is then calculated with equation 2 
 moles dye per mole protein = A494/ H’ x protein concentration (M)  (2) 
where H’ is the extinction coefficient of the fluorescence dye. 
2.4.2.2 Liposomal encapsulation of TNF-Į and DMXAA
TNF-Į and DMXAA liposomes were prepared by hydration of a 10 µmol 
SPC/Cholesterol/cyanur-PEG2000-PE molar ratio 65/30/5/ film with 100 µl TNF-Į (1 
mg/ml) or 100 µl DMXAA (20 mg/ml), respectively. Unilamellar liposomes were formed 
by sonicating the liposomes 3 times for 5 seconds with 3 cycles. The particle size was 
thereafter determined as described in section 2.5.1. Non-encapsulated TNF-Į or DMXAA 
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was removed by gel permeation chromatography using a Sepharose 4B column and a 0.9 
% NaCl solution as eluant.
Encapsulation efficiency was given as Pg TNF-alpha/Pmol lipid and was established by 
measuring the amount of lipid using the phosphate assay (section 2.5.2) and the 
fluorescence of the FITC labeled TNF-Į or by measuring protein concentration.
The amount of encapsulated DMXAA was determined by measuring the fluorescence of 
DMXAA. A calibration curve for DMXAA in 0.9 % NaCl solution was obtained using a 
LS 30 Fluorescence Spectrometer (Perkin-Elmer, Jügesheim, Germany) with an 
excitation wavelength of 350 nm and an emission of 412 nm, after which the fluorescence 
of the unknown sample was measured.  
2.4.3 Coupling proteins to the liposomes 
Two different anchor lipids (Ng-PE and Cyanur-PEG-PE anchor) were compared 
and used to couple proteins to the liposomes. Rat anti-mouse VCAM monoclonal 
antibody (mAb) (M/K-271) was used as homing devices. Control liposomes were coupled 
to an irrelevant IgG (human fractionated IgG with ~70% IgG1 content or purified rat 
IgG1) or to bovine serum albumin (BSA) (grade V). Coupling was performed in the 
optimal 1:1000 protein:lipid molar ratio [Hansen et al., 1995]. 
To form a protein linkage to liposomal Ng-PE, 6 mg EDC was added to 10 Pmol 
liposomes in PBS (pH 7.4) followed by an incubation period of 4 h at room temperature. 
Antibodies were added and incubated overnight at room temperature. The ILs were 
separated from unbound antibodies by gel permeation chromatography using a Sepharose 
4B column and 0.9 % NaCl solution as eluant.  
To couple the proteins to the cyanur anchor the calculated amount of antibody was added 
to liposomes in borate buffer pH 8.8 (solution 1:4.77 g Borax in 250 ml H2O; solution 
2:0.1 M HCl; Borate buffer:75 ml solution 1, 25 ml solution 2) and incubated at room 
temperature for about 16 h. Unbound antibodies were separated by gel permeation 
chromatography using a Sepharose 4B column with a 0.9% NaCl solution as eluant.
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2.5 Liposome characterization 
Liposomes were characterized with respect to particle size by dynamic light 
scattering (Malvern autosizer IIc, Malvern, UK), and with respect to phospholipid 
concentration [Ames and Dubin, 1960]. The concentration of coupled proteins was 
determined with a modified Lowry assay [Peterson, 1977].
2.5.1 Particle sizing 
Dynamic light scattering can be used to measure the size of small particles with a 
diameter of 5-5000 nm. Particles of this size are characterized by their constant random 
thermal movement. When monochromatic light hits a particle, the particle movement 
causes the intensity of light scattering to vary with time. The principle is that larger 
particles move slower than small particles, which causes the rate of fluctuation of the 
scattered light to be slower for large particles as compared to small particles [Malvern, 
1993]. These properties make it possible to calculate the diffusion coefficient of a 
particle. The diffusion coefficient can be used to calculate the hydrodynamic radius by 
using the Stroke-Einstein equation (3) 
r+ = k%T/6SKD   (3) 
where k% is Bolzmann’s constant, T is temperature, K is the fluid viscosity and D is the 
diffusion time [Øgendahl, 2001]. After analysis the hydrodynamic diameter and the 
polydisperisty is given. The polydispersity is a factor that describes the homogeneity of 
the sample and lies in the range of 0-1, with 0 being very homogenous [Constantinides 
and Yiv, 1995]. Polydispersity should be lower than 0.5, as samples with a higher 
polydispersity are not homogenous and not suited for the technique.
 Measurements were carried out on a Malvern Autosizer 2c (Malvern Instruments, 
Worcestershire, UK). 1 ml 0.9 % NaCl solution was filtered sterile (Sterilfilter Satorius, 
0,22ȝm), placed in a cuvette and approx. 30 µl liposome suspension was added. 
Thereafter the size (nm) and polydispersity was given as a mean of 3 times 10 
measurements.  
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2.5.2 Phospholipid concentration determination 
Phosphate determination was performed as described by Ames and Dubin [1960]. 
Briefly, this method is based on a colorimetric determination of PO4
3-
. The liposomal 
phospholipids were oxidized with perchloric acid to produce inorganic phosphate, which 
reacts to phosphomolybdate acid. This can be converted quantitatively to a blue 
compound after being reduced by ascorbic acid while heated.
A calibration curve was made with a 65 mM phosphate standard. Known amounts 
of phosphate standard, from 2-65 nmol, were added to glass test tubes. Small amounts of 
the liposome solution (15-30 µl) were transferred to a glass test tube. Thereafter 0.2 ml 
perchloric acid was added to each tube, the tubes were covered with aluminum foil to 
prevent evaporation, and the mixtures were incubated for 30 min on a heating block at 
180qC. The test tubes were cooled down and 2 ml hexa-ammoniummolybdate solution 
(2.2 g (NH
4
)
6
Mo
7
O
24
× 4H
2
O, 14.3 ml conc. sulfuric acid ad 1000 ml dH2O) and 0.25 ml 
10 % ascorbic acid solution (w/v) were added to each test tube. The mixture was 
vortexed, incubated for 10 min at 100qC in a water bath and thereafter cooled down in 
cold water. Absorbance was measured at 812 nm. 
2.5.3 Protein concentration determination according to Peterson-Lowry 
A modified Peterson-Lowry assay was used to determine the amount of protein 
coupled to the liposome. The advantage of this method is that the phospholipids only 
interfere minimally and that other interfering substances can be removed by precipitating 
the proteins prior to running the assay. The principle behind the Lowry method of 
determining protein concentrations lies in the reactivity of the peptide nitrogens with the 
copper [II] ions under alkaline conditions and the subsequent reduction of the Folin-
Ciocalteau phosphomolybdic acid to heteropolymolybdenum blue by the copper-
catalyzed oxidation of aromatic acids [Dunn, 1992]  
Briefly, a calibration curve was produced with either human IgG or BSA as 
reference depending on the protein coupled to the liposome. Known amounts of protein 
between 2-12 µg were transferred to Eppendorf tubes. The protein concentration in the 
liposome samples was measured in 10-30 µl liposome suspension. dH2O was added to 
each tube to give a final volume of 1 ml. The proteins were then precipitated. First, 50 µl 
0.3% sodiumdeoxycholate was added to each tube; the samples were vortexed and 
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incubated for 10 min at room temperature. Then 100 µl 70% trichloracetic acid was added 
and the samples were vortexed and centrifuged for 20 min at 11.000 rpm at 4 ºC in an 
Eppendorf centrifuge. The supernatant was discarded and the pellet was dissolved in 1 ml 
solution C consisting of 49 volume parts of solution A (4 g NaOH, 20 g Na2CO3, 1L 
milliQ H2O) and 1 volume part of solution B (0.5 g CuSO4 x 5 H2O, 1 g Na-citrate, 100 
ml milliQ H2O) and vortexed and incubated for 10 min at room temperature. Finally, 50 
µl of Folin-Ciocalteau reagent was added and after vortexing, the samples were incubated 
for 30 min in the dark at room temperature. Absorbance was measured at 750 nm.  
2.6 VCAM expression and liposome targeting to bEnd3 cells in
vitro
2.6.1 VCAM expression and liposome binding using flow cytometry (FACS) 
analysis
Flow cytometry measures the fluorescence and optical characteristics of single 
cells by using the principles of light scattering, light excitation, and emission of 
fluorochrome molecules to generate specific multi-parameter data from particles and 
cells. Inside a flow cytometer, cells in suspension are drawn into a stream created by a 
surrounding sheath of isotonic fluid that creates laminar flow, allowing the cells to pass 
individually through an interrogation point. Lasers are most often used as a light source in 
flow cytometry. As the cells of interest intercept the light source they scatter light and 
fluorochromes are excited to a higher energy state. This energy is released as a photon of 
light with specific spectral properties unique to different fluorochromes. The emitted light 
signals are detected by photomultiplier tubes and digitized for computer analysis [Brown 
and Wittwer, 2000].  
2.6.1.1 bEnd3 cells expression of VCAM  
VCAM expression on activated bEnd3 cells was analyzed by flow cytometry. 
bEnd3 cells were incubated with 50 ng/ml TNF-D for 4 hours, rinsed twice in washing 
buffer (PBS containing 1% BSA), detached with 0.025% EDTA, and fixed in 4% neutral 
buffered paraformaldehyde for 10 min at room temperature. After two more washes, cells 
were stained with rat anti-mouse VCAM mAb MK271 (10 Pg/ml) for one hour on ice and 
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labeled with FITC-conjugated goat anti-rat secondary antibody for 30 min on ice, prior to 
analysis on a flow cytometer (BD Biosciences, San Jose, CA, USA). 
2.6.1.2 Liposome binding to bEnd3 cells 
Liposomal binding to the bEnd3 cells was determined by FACS analysis. bEnd3 
cells were seeded in 96-well microtiter plates (density: 1x10
4
 cells/well) 24 hours prior to 
the assay. The cells were activated with TNF-D (50 ng/ml) for 4 hours to ensure VCAM 
expression. Seven different liposome preparations carrying a DiO label were investigated: 
three with the NgPE anchor anti-VCAM mAb-liposomes (ĮVCAM-NL) human IgG 
(hIgG-NL) of irrelevant specificity and albumin-liposomes (Alb-NL) and four with the 
cyanur anchor; anti-VCAM mAb-liposomes (Į-VCAM-CL), liposomes conjugated to rat 
IgG1 (rIgG-CL) or human IgG (hIgG-CL) of irrelevant specificity and albumin-liposomes 
(Alb-CL). The liposomes (75 nmol) were incubated with the cells for 1 hour at 4°C in 
normal cell medium. Unbound liposomes were removed by washing with 0.1 M PBS with 
1 mM CaCl2 and 0.5 mM MgCl2. The cells were detached with 0.025% EDTA and 
liposomal binding was analyzed on the flow cytometer (BD Biosciences, San Jose, CA, 
USA). 
2.6.2 Fluorescence- based cell assay 
The binding of VCAM-directed liposomes to murine endothelial cells was 
measured using a fluorescence-based cell assay and compared to control liposomes. 
Murine bEnd3 endothelial cells were seeded and activated as described in section 2.6.2. 
Five different liposome preparations (see 2.4.) carrying a DiO label were investigated. 
The liposomes (75 nmol) were incubated with the cells for 1 hour at 4°C in normal cell 
medium. Unbound liposomes were removed by washing with 0.1 M PBS (pH 7.4) 
containing 1 mM CaCl2 and 0.5 mM MgCl2, and the liposomal binding was analyzed in a 
FLUOstar Optima micro plate reader (BMG Labtech, Offenburg, Germany).  
To investigate whether the unspecific binding of control liposomes to endothelial cells 
was due to any interaction with the Fc receptor, a blocking assay was performed. 30 min 
prior to the addition of the liposomes, 2 Pg / 1 × 106 cells rat anti-mouse Fc-receptor 
antibody or 60 µmol plain liposomes was added to the cells. Thereafter the liposomes 
were added and the same procedure as described above was followed. 
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The internalization of VCAM-targeted liposomes was investigated using the acid 
wash method. This method uses the principle that the antigen/antibody binding is 
destroyed under acidic conditions and has the advantage that it straightforwardly 
discriminates and quantifies between cell surface bound and internalized antibody-
coupled particles [Liu et al., 2007b].
To quantify the internalization of VCAM-directed liposomes upon binding to 
bEnd3 endothelial cells, the same procedure was followed as described above except that 
the cells were incubated with liposomes for 2 hours at 37ºC. Thereafter, unbound 
liposomes were removed by washing with PBS containing 1 mM CaCl2 and 0.5 mM 
MgCl2 and liposome binding was measured. To determine the fraction of cell-associated 
liposomes that were internalized, the cells were stripped of their surface-bound liposomes 
by one wash for 5 min with citrate buffer (pH 3.0) followed by one wash with PBS. The 
remaining cell-associated liposomes were considered internalized. 
2.6.3 Dynamic flow assay 
In order to simulate the in vivo binding of the liposomes to the endothelial cells 
under shear force conditions, a dynamic flow assay was performed as previously 
described [Bendas et al., 1998; Kessner et al., 2001].  
Figure 12. Schematic presentation of the laminar flow chamber. Immunoliposomes in the flow medium 
were rinsed through the chamber by hydrodynamic drag to interact with VCAM –expressing cells [Bendas 
et al., 1998]. 
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Briefly, the endothelial cells were seeded on circular (18 mm) coverslips (5 ×105 cells) 
24 hours prior to the assay. The cells were activated with TNF-D (50 ng/ml) for 4 hours 
and subsequently washed once with PBS. The coverslips were inserted into a double flow 
chamber (Fig.12). Each chamber was perfused with 5 ml of RPMI 1640 medium 
containing 1% penicillin/streptomycin, 10% FCS and 0.5 µM liposome dispersion for 20 
hours at a shear rate mimicking capillary blood flow (about 200 s-1) using a peristaltic 
pump at approx. 37°C. Two different liposome preparations carrying a rhodamine-label, 
were investigated; Į-VCAM-CL and hIgG-CL. At different time points (t = 0, 1 hour, 2 
hours and 20 hours), the flow was stopped and pictures of the liposomal binding to the 
cell layer were taken through an inverted fluorescence microscope Axiovert 200 equipped 
with an AxioCam MRc camera (Carl Zeiss, Germany). 
2.7 Į-VCAM IL targeting and biodistribution in vivo 
 2.7.1 Xenograft mouse model and biodistribution studies 
Female CD1 nude mice (Charles River Laboratories, Germany) were housed in 
cages with free access to food and water with a 12 hour light/dark cycle. Human Colo 677 
xenograft tumors were created by a subcutaneous co-injection of 1 × 10
6
 Colo 677 cells 
with Matrigel (BD Science, Heidelberg, Germany) diluted 1:1 into one flank of 4 - 5 
week-old mice. The tumor size was measured every second day with a caliper in three 
perpendicular directions a, b and c, and tumor volumes were calculated according to the 
formula V = ʌ/6 × a × b × c. When the tumors had grown to 200 - 500 mm3, the mice 
were injected with 0.5 Pmol liposomes into the tail vein. Three different liposome 
preparations were investigated; D-VCAM-Ls, irrelevant IgG-liposomes and Alb-L (n = 3 
per group), all containing DiO as a fluorescent label. The mice were sacrificed either 30 
min or 24 hours after liposome injection. Experiments were terminated by transcardial 
perfusion of deeply anesthetized mice with PBS for 10 min and major organs and tumors 
were snap frozen in dry ice/isopentane slush and stored at -80°C until further use. The 
organs and tumors were cut into 5 Pm sections on a Leica CM 3050 G cryostat (Leica, 
Wetzlar, Germany) and were either used directly or stored at - 80°C. 
Total liposome tumor accumulation and biodistribution were investigated using 
Tritium-labeled liposomes. [
3
H]-labeled liposomes coupled to either anti-VCAM 
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antibody or an irrelevant human IgG were injected i.v. at a dose of 0.5 µmol 
liposome/mouse (n = 4-5 mice per group). The animals were anesthetized after 24 hours 
and blood was collected by heart puncture. This was followed by a transcardial perfusion 
with PBS for 10 min the before liver, spleen, kidney, lungs, heart, skin, muscle and tumor 
were removed, weighed and stored at -20°C until further use. To measure the amount of 
accumulated radioactive liposomes in the organs and tumor, the tissues were 
homogenized using a Potter Elvehjelm tube in 3 ml homogenization buffer per g tissue. 
Radioactivity was measured in 500 µl tissue homogenate after adding 100 µl of 10% SDS 
and 4 ml scintillation liquid (Ultima Gold). Blood samples were allowed to clot for 3 
hours and centrifuged for 20 min at 13.520 g at 4 ºC.
2.7.2 Fluorescence microscopy of tissue sections 
Cryosections of tumors and organs were thawed, fixed in 4 % paraformaldehyde 
for 10 min and incubated with one of the following primary antibodies: rat anti-mouse 
CD31 or rat anti-mouse Meca32 against endothelial cells; rat anti-mouse BM8 against 
macrophages; rat anti-mouse CD11b against macrophages and dendritic cells. Sections 
were incubated with primary antibodies for 1 hour at room temperature. Excess primary 
antibody was removed by three successive washes for 5 min with PBS. Thereafter, Alexa 
Fluor 568 conjugated secondary antibody was applied for one hour at room temperature, 
followed by three washes with PBS. Coverslips were mounted with a fluorescence-
mounting medium (Dako, Glostrup, Denmark). The sections were stored in the dark at 
4°C until further analysis. Overlay analysis was performed using AxioVision software 
(Carl Zeiss AxioVision release 4.6). Percentages of liposomes co-localized with the 
endothelium were determined in four randomized microscopic fields and calculated as the 
ratio between the amount of co-localised pixels x 100 and the total number of green 
pixels. The co-localization percentages are given as mean ± SD.  
2.8 Cytotoxicity studies 
Both TNF-D and DMXAA influence cells in many different ways. Therefore the 
two drugs themselves were tested for any cytotoxic effect that might act in synergy with 
the induction of coagulation in the tumor. 
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2.8.1 Propidium iodide (PI) assay
PI is a DNA-binding agent that is impermeable to the membranes of viable cells, 
but penetrates plasma membranes of dead cells and binds to the DNA of dead cells. PI is 
known as an indicator of necrosis or late-stage apoptosis .5 × 10
4
 bEnd3 cells / well were 
plated out in 6 well plates and allowed to attach overnight. The following day the cells 
were treated with TNF-D (50 – 200 ng/ml) for 24 and 48 hours in the incubator. 
Subsequently, PI solution (5µg/ml) was added to each well and the cells were incubated 
for 5 min at 37qC. Thereafter the cells were analyzed in a flow cytometer. PI has an 
excitation wavelength of 488 nm and an emission of 630 nm. 
2.8.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) 
assay
The MTT assay is a quantitative colorimetric assay used to measure mammalian 
cell survival and cell proliferation. The assay measures cellular respiration by determining 
the mitochondrial activity. MTT is a pale yellow substrate that is cleaved by living cells 
to yield a dark blue formazan product. The process requires active mitochondria, and the 
amount of formazan produced is proportional to the number of living cells present in a 
given culture [Hayton et al., 2003].
 The bEnd3 cells were seeded out with a density of 5 × 10
3
 cells/ well and allowed 
to attach overnight. The cells were treated with TNF-Į in a range of 1 – 10.000 ng /ml 
and with DMXAA in a range of 0.2 – 3000 µg/ml for 24, 48 and 72 hours. One hour 
before assay termination, 20 µl MTT solution (5mg/ml MTT in 0.1M PBS pH 7.4) was 
added to each well and the cells were incubated for 1 hour in the incubator. The reaction 
was then stopped by lysing the cells and dissolving the formazan salt by adding 150 µl 
acidic isopropanol solution (160 µl HCl in 50 ml isopropanol) to each well. After 
extensive mixing with a pipette, the formazan salt was allowed to dissolve completely at 
4qC for 2 hours. Finally the absorbance was measured at 580 nm. The background 
absorbance was also measured at 690 nm and subtracted. 
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2.9 TNF-D induced TF expression and activity in vitro
 2.9.1 TF cell-based enzyme-linked Immunosorbent Assay (ELISA) 
A cell-based ELISA was developed to measure the relative amount of TF 
expressed on the endothelial cells after TNF-D stimulation. bEnd3 cells and/or B16F10 
cells were seeded out with a density of 1 × 10
4
 cells/well and allowed to attach overnight. 
B16F10 cells are melanoma cells that have been shown to express tissue factor 
constitutively and are therefore used as a positive control. The bEnd3 cells were activated 
with 50 ng/ml TNF-D for 6 hours after which a sandwich ELISA was carried out on top 
of the cells. The cells were washed twice with 0.1 M PBS (pH 7.4) and thereafter fixed 
with 1 % paraformaldehyde for 10 min at 4qC. The cells were rinsed twice with PBS; 
unspecific antibody binding was inhibited by incubating the cells with blocking solution 
(0.1 M PBS pH 7.4, 0.5 % BSA) for 15 min. The cells were stained with 10 µg/ml rabbit 
anti-mouse tissue factor antibody for 45 min at room temperature, washed 3 times with 
PBS and labeled with 1:5000 goat anti-rabbit horse radish peroxidase conjugated 
secondary antibody for 30 min at room temperature. After three washes with PBS, 100 µl 
of the peroxidase substrate TMB was added and the reaction was allowed to run for 10 
min. Thereafter the reaction was stopped with 2 N H2SO4 and absorbance was measured 
at 450 nm.  
2.9.2 TNF-Į induced TF expression analyzed with flow cytometry
The cell-based ELISA does not analyze the TF expression on each single cell, but 
on the cells as a population. To investigate the TF expression on single cells, flow 
cytometry was used. 
bEnd3 cells were incubated with 50 ng/ml TNF-D in serum depleted (normal 
medium with 1% FCS) for 6, 12 and 24 hours. After two washes in 0.1 M PBS (pH 7.4) 
containing 1 mM CaCl2, cells were stained with rabbit anti-mouse tissue factor (200 
Pg/ml) in incubation buffer (0.1 M PBS (pH 7.4), 1 mM CaCl2, 1% BSA) for one hour on 
ice and labeled with FITC-conjugated goat anti-rat secondary antibody in incubation 
buffer for 30 min on ice. Before analysis the cells were detached from the plates by 
washing the cells twice with 0.1 M PBS (pH 7.4) and incubation with 0.025% EDTA for 
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15 min at 37qC. The cells were finally analyzed by flow cytometry (BD Biosciences, San 
Jose, CA, USA). 
2.9.3 Western Blot 
Western Blot analysis was used to investigate the total tissue factor expression by 
b.End.3 cells and in tumor tissue from animals treated with TNF-Į encapsulated 
liposomes.  
2.9.3.1 Cell lysis 
bEnd3 cells were seeded in T25 flasks and activated with 50 ng/ml TNF-D for 6 
hours. Thereafter the cells were rinsed twice with PBS. Protease inhibitor cocktail 
(Roche, Basel, Switzerland) was added to the lysis buffer (50 mM Tris/HCl; 100 mM 
NaCl, 1 mM EGTA, 10 mM, 1% triton X-100, 0.2 % SDS) in a dilution of 1:100 and 400 
Pl was added to each flask. The cells were scraped off with a rubber scraper, transferred 
to an Eppendorf tube and kept on ice. To disperse any large aggregates, the cells were run 
through a 27 G needle 4-5 times. Thereafter the protein concentration was measured using 
a Bio-Rad Dc Kit (Bio-Rad, CA, USA) according to the manufacturere’s instructions. The 
lysates could be used directly or stored at -20qC until later use.  
2.9.3.2 Tissue homogenization 
The tumor tissue was homogenized in a ratio of 1 g tumor tissue to 1 ml lysis 
buffer (50 mM Tris/HCl, 100 mM NaCl, 1 mM EGTA, 10 mM MgCl2, 1 % Triton X-
100, 0.1% SDS) added 1 complete® tablet (Roche, Basel, Switzerland) with protease 
inhibitors per 50 ml. First, the tissue was homogenized with a Potter Elvehjem tube (5 
strokes) and thereafter with an Ultra-Turrax (KIA®, Wilmington, USA) for 3 times 20 
seconds. The protein concentration was then measured as described above. 
2.9.3.3 SDS page 
A SDS page is run to separate the sample proteins by size. The samples were 
prepared by mixing 20 Pg protein with NuPage LDS sample buffer (1:4) and reducing 
agent (0.25 % mercaptoethanol, 1:10), after which the samples were heated for 10 min at 
70qC and then loaded. A NuPage® 4-12% Bis-Tris gel with MOPS running buffer was 
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prepared by washing the gel in distilled water, removing the comb and washing the wells. 
The samples were loaded and run, first, for 10 min at 150 V and then for 40 min at 200 V. 
2.9.3.4 Immunoblotting 
While the gel was running, the blotting pads, filter paper and nitrocellulose 
membrane were soaked in NuPAGE transfer buffer mixed with 10% methanol. The 
proteins were transferred to a 0.20 µm nitrocellulose membrane (LKB Diagnostics) using 
NuPAGE transfer buffer mixed with 10% methanol to provide optimal protein transfer at 
30 V for 1 hour. Membranes were blocked for nonspecific immunoreactivity by 
incubation for 1 hour with 5 % skimmed milk powder dissolved in 0.1 M PBS, (pH 7.4). 
The membrane was thereafter incubated with primary antibody solution containing 5 
Pg/ml rabbit anti-mouse tissue factor in 0.1 M PBS, (pH 7.4) with 0.05% Tween 20, 
overnight at 4 qC. The membrane was washed 3 times 10 min with 0.1 M PBS containing 
0.05 % Tween 20. Antibody binding was detected with horse radish peroxidase-coupled 
goat anti-rabbit immunoglobulin 1:10,000 in blocking buffer (5 % skimmed milk powder 
in 0.1 M PBS (pH 7.4)) for 1 hour at room temperature. The membrane was washed 3 
times 10 min with PBS containing 0.05% Tween 20. The immunoreaction was visualized 
using the chemiluminescent ELC plus Western Blot reagent (GE Healthcare Life 
Sciences, Buckinghamshire, UK) and Amersham Hyperfilm ELC (Amersham, 
Buckinghamshire, UK).
2.9.4 TF induced coagulation
To investigate whether the up-regulated tissue factor was active, a simple 
coagulation assay was developed. A single-stage assay where CaCl2 was added to a 
mixture of cell lysate and citrated mouse plasma was performed. The mouse plasma 
contains all the components except tissue factor needed for fibrin formation and clotting. 
Therefore clotting is dependent on the presence of the active tissue factor protein 
expressed by the cells. The clotting time was measured by detecting changes in the 
intensity of light scattered by the samples due to the increased turbidity caused by the 
clotting particles [Seetharam et al., 2003].  
2.9.4.1 Coagulation assay cell lysates
The bEnd3 or B16F10 cells were seeded out in 6 well plates with a density of 5 × 
10
4
 cells/well. The cells were allowed to adhere overnight in normal medium. The next 
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day the cells were activated in serum-depleted cell medium containing 1% FCS and 50 
ng/ml TNF-Į or 800 µg/ml DMXAA and stimulated for different time points 4 - 24 hours. 
The cell lysates were prepared according to Kim et al. [2001]. Briefly, the cells were 
washed twice with 0.1 M PBS (pH 7.4) and lysed in 100 µl lysis buffer (15 mM octyl-ß-D 
glucopyranoside in 25 mM HEPES buffer). The cell lysates were transferred to 
Eppendorf tubes, vortexed for 1 min and incubated at 37 qC for 15 min. Thereafter 200 µl 
of 25 mM HEPES buffer was added to each tube and the cell lysates were ready for use. 
2.9.4.2 Single-stage coagulation assay 
The assay was carried out in a flat-bottomed 96 well plate. To each well 50 µl cell 
lysate and 50 µl citrated mouse plasma (Equitech Bio, Texas, USA) were added and the 
mixture was incubated for 1 min at 37qC. Thereafter 50 µl 25 mM CaCl2 was added to 
each well and the absorbance was measured continuously at 405 nm with intervals of 8 
sec for 2 min using a FLUOstar Optima microplate reader (BMG Labtech, Offenburg, 
Germany). Negative controls were performed where citrated mouse plasma, cell lysate or 
CaCl2 were omitted. Cell lysates from B16F10 cells were used as positive controls. 
Clotting could be delayed or completely inhibited by pre-incubating the cell lysates with a 
rabbit anti-mouse tissue factor antibody (10 µg/ml) for 30 min prior to starting the assay. 
2.10 Treatment of colo 677 tumors with DMXAA and TNF-Į
liposomes in vivo
2.10.1 Treatment with TNF-alpha and DMXAA liposomes 
The Colo 677 tumors were grown as previously described in section 2.7.1. When 
the tumors reached a size of 150 - 200 mm the animals were treated with one bolus 
injection of TNF-D loaded Į-VCAM-L or TNF-D-loaded rIgG-L in a concentration of 
200 µg/kg TNF-Į. The tumor size was measured daily until the tumors reached a size of 
900 - 1000 mm
3
, after which the animals were sacrificed. A control group of mice were 
not treated. Each group contained 10 animals. The tumors from four animals in each 
group were either fixed in 4 % formaldehyde overnight or embedded in paraffin, or snap 
frozen used for TNF-Į ELISA.
Materials and Methods 
________________________________________________________________________
54 
2.10.1.1 Tissue factor expression in tumors treated with TNF-L after 24 and 72 hours
A small pilot experiment was carried out in which the expression of TF after 
treatment with VCAM targeted TNF-L and empty liposomes 24 hours and 72 hours after 
treatment. Western blot was used to investigate whether TF was upregulated. 
 The Colo 677 tumors were grown and when the tumors reached a size of 150 - 200 mm 
the animals were treated with one bolus injection of either TNF-D loaded Į-VCAM-L or 
empty Į-VCAM-L in a concentration of 200 µg/kg TNF-Į. After 24 and 72 hours the 
animals were sacrificed, the tumors immediately snap frozen and stored at -80ºC until 
further use. 
 The tumors were then homogenized. First, 1 g tumor tissue was homogenized 
using 1 ml lysis buffer (50 mM Tris/HCl, 100 mM NaCl, 1 mM EGTA, 10 mM MgCl2, 1 
% Triton X-100) added one complete® tablet with protease inhibitors (Roche, Basel, 
Switzerland) per 50 ml. Secondly, the tissue was homogenized with a Potter Elvehjem 
tube (5 strokes) and then with an Ultra-Turrax for 3 times 10 seconds. Thereafter the 
same Western Blot procedure was followed as described in section 2.8.3. 
2.10.2 TNF-D ELISA 
A TNF-Į ELISA was carried out to measure the amount of TNF-Į accumulated in 
the tumors after treatment. First, 1 g tumor tissue was homogenized using 1 ml lysis 
buffer (50 mM Tris/HCl, 100 mM NaCl, 1 mM EGTA, 10 mM MgCl2, 1 % Triton X-
100) added one complete® tablet with protease inhibitors per 50 ml. Then the tissue was 
homogenized with a Potter Elvehjem tube (5 strokes) and further homogenized with an 
Ultra-Turrax for 3 times 10 seconds. The homogenate was centrifuged at 11000 rpm for 
20 min at 4qC in a Eppendorf centrifuge. The supernatant was collected and the protein 
concentration was measured with a Bio-Rad Dc Kit according to the manufacturere’s 
recommendations. The amount of TNF-Į was measured in the supernatants using a TNF-
Į ELISA kit according to the manufactures instructions. 
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2.10.3 Immunohistochemistry and histology 
2.10.3.1 Fluorescence microscopy of tissue sections 
Cryosections of tumors were thawed, fixed in 4 % paraformaldehyde for 10 min 
and incubated with rabbit anti-mouse tissue factor (10 µg/ml). Sections were incubated 
with primary antibodies for 1 hour at room temperature. Excess primary antibody was 
removed by three successive washes for 5 min with PBS. Thereafter, Alexa Fluor 568 
conjugated secondary antibody was applied for one hour at room temperature, followed 
by three washes with PBS. Coverslips were mounted with a fluorescence-mounting 
medium (Dako, Glostrup, Denmark). The sections were stored in the dark at 4°C until 
further analysis.
2.10.3.2 In situ TUNEL assay 
In order to investigate whether treatment with TNF-Į and DMXAA induced cell 
death in the tumor a terminal deoxynucleotidyl tranferase dUTP nick end labeling 
(TUNEL) assay was employed.  
 Apoptosis is a well controlled process, which among other things, results in DNA 
fragmentation. The TUNEL assay takes advantage of the apoptosis-induced single and 
double strand breaks by labeling the free 3’OH DNA termini with digoxigenin-labeled 
and unlabeled nucleotides. The reaction is catalyzed by the enzyme deoxynuclotidyl 
transferase, which catalyses a template independent of the addition of nucleotide 
triphosphates to the 3’OH ends. The DNA fragments labeled with digoxigenin are then 
labeled with a peroxidase labeled anti-digoxigenin antibody, which enzymatically 
generates an intense localized staining of chromogenic substrates such as 
diaminobenzidine (DAB).    
The TUNEL assay was carried out according to the manufacturere’s 
recommendations. Briefly, 20 µm paraformaldehyde-fixed tumor cryosections were post-
fixed in pre-cooled ethanol:acetic acid (2:1 v/v) for 5 min at -20ºC. Thereafter the 
sections were washed two times 5 min in PBS. Endogenous peroxidase activity was 
quenched in 3 % H2O2 in PBS for 5 min at RT and thereafter washed twice with PBS for 
5 min. The sections were equilibrated with EQULIBRATION BUFFER for 10 seconds. 
Excess liquid was tapped off and immediately thereafter, working-strength TdT enzyme 
was added. The sections were incubated for 1 hour in a humid chamber at 37 ºC. The 
reaction is stopped by washing the sections twice in stop/wash buffer for 15 sec agitation 
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and thereafter for 10 min. The sections are washed 3 times in PBS for 5 min and excess of 
liquid is removed. The sections were incubated with anti-digoxigenin peroxidase 
conjugated antibody for 30 min in a humid chamber at RT. The sections were washed 4 
times in PBS for 2 min. Thereafter the substrate DAB was applied for 6 min. DAB was in 
0.01% H2O2 0.05 M Tris/HCl buffer. The sections were washed in demineralized water 
twice for 5 min. Tissue sections were placed on slides and coverslips were mounted with 
Pertex mounting medium. Some sections were not exposed to TdT and served as negative 
controls.
 To investigate whether there was a quantitative difference in the amount of 
apoptotic cells within the different treatment groups, two different fields were counted 
from 4 tumors in each group. Both fields were in the periphery, one in a hot spot area and 
one in a normal area. 
2.11 Statistical analysis 
Statistical significance between groups in the in vitro binding assays and in the in 
vivo biodistribution experiment was calculated using unpaired Student’s t-test. 
Significance was assumed at a p-value < 0.05. Statistical significance between multiple 
groups in the treatment experiment were calculated using one way analysis of variance 
(ANOVA), and post-hoc the Newman-Keuls test was used to test for significance 
between the individual groups. 
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3. Results and Discussion 
The concept of targeting liposomes to tumor vasculature provides an opportunity 
for specific and effective delivery of drugs to the diseased sites and is an appealing 
strategy for therapy. The accessibility and stability of tumor endothelial cells makes them 
convenient targets, both for drug delivery and drug action. Targeting ILs against 
endothelial cell surface antigens has been used to target the endothelium [Kessner et al.,
2001; Voinea et al., 2005]. The cell adhesion molecule VCAM is one promising target 
receptor and plays a role in the pathogenesis of inflammatory diseases such as 
atherosclerosis, rheumatoid arthritis and multiple sclerosis [Dienst et al., 2005]. VCAM 
expression is inducible and is selectively expressed on activated endothelium, i.e. in 
human malignant tumors [Guccione et al., 2004]. Firstly, the targetability of endothelial 
cells by VCAM-targeting liposomes was investigated in vitro and in vivo. Subsequently 
experiments were carried out to ensure that the liposomes targeted tumor vasculature 
selectively and not the vasculature in other organs. 
3.1 In vitro targeting of VCAM-1 
The first step in the development of an Į-VCAM liposomal drug delivery system 
was to investigate the targetability of Į-VCAM-coupled liposomes to activated 
endothelium in vitro.
3.1.1 VCAM-1 expression in two different endothelial cells 
The two murine endothelial cell lines, 2F2B and bEnd3, were chosen for the 
establishment of an in vitro model of vascular liposomal targeting. 2F2B is a murine 
endothelial cell line isolated from a Kaposi tumor [Walter-Yohrlin et al., 2004], while 
bEnd3 is a brain endothelial cell line that is used to study adhesion molecule expression 
because the cells responds well to cytokine activation. The two different cell lines were 
investigated to ensure that activated endothelium could be targeted in general. 
  Flow cytometry was used to establish that the two cell lines indeed expressed 
VCAM on their surface. Although the non-activated bEnd3 cells (A) and 2F2B cells (not 
shown) also exhibited some surface expression of VCAM, 4 hours of incubation with 
TNF-D increased VCAM expression on both bEnd3 cells (B) and 2F2B cells (C) as 
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illustrated in Fig. 13. Based on these data, all further experiments were carried out with 
cells activated for 4 hours with TNF-D.
Figure 13. VCAM expression on bEnd3 cells and 2F2B cells after 4 hours. A: VCAM expression on non-
activated bEnd3 cells; B: VCAM expression on TNF-Į (50 ng/ml, 4 h) activated bEnd3 cells; C: VCAM 
expression on TNF-Į (50 ng/ml, 4 h) activated 2F2B cells. D: VCAM staining of activated bEnd3 cells. The 
histograms A to C are representative for 3 or more similar diagrams.  
3.1.2 Targeting VCAM on activated endothelium in vitro with Į-VCAM 
liposomes
 Fluorescence-labeled liposomes were prepared with various proteins coupled to 
their surface via an NgPE-anchor (Fig. 14). Liposomes carrying anti-VCAM mAb (D-
VCAM-NL) where compared to liposomes carrying a human IgG of irrelevant specificity 
(hIgG-NL), or albumin-conjugated liposomes (Alb-NL) in a fluorescence-based cell assay 
using both cell lines. As illustrated in Fig. 14A, the binding of the Į-VCAM-NL to 2F2B 
cells was higher than that of the two control liposome-formulations coupled to hIgG and 
albumin, respectively, although the differences were not statistically significant. The 
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same observation was made in bEnd3 cells, where the binding of D-VCAM-NL was 
higher than that of control liposomes and even reached statistical significance with the 
Alb-NL (p<0.05) (Fig. 14B).
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Figure 14. Targeting NgPE- liposomes to VCAM-1 expressing 2F2B cells and bEnd3 cells using plate 
reader analysis. A comparison of the binding efficiency of Į-VCAM-NL and hIgG-NL or Alb-NL is made 
in 2F2B cells (A) and bEnd3 cells (B) * p < 0.05 Į-VCAM-NL vs. Alb-NL. Data points represent the 
average of at least three experiments, error bars are SD.  
BA
To investigate whether the relatively high binding of the control hIgG-NL was 
mediated via Fc-receptors, which have been reported to be up-regulated on activated 
endothelium [Ryan, 1986; Pan et al., 1998], the same assay was carried out in the 
presence of a Fc-receptor blocking antibody. The inhibition of binding FITC-labeled 
human IgG to activated 2F2B cells was investigated using the Į-Fc-receptor antibody. As 
seen in Fig. 15A, 50 % of the binding was inhibited. However, when repeating the 
experiment with hIgG-NL instead of FITC-labeled human IgG, the binding was only 
partially inhibited (approximately 25 %) (Fig. 15B). The fact that the binding was not 
totally abolished suggests that other mechanisms could be involved in the unspecific 
binding of the hIgG-NL. Fc-receptors are mostly expressed by monocytes, macrophages 
and lymphocytes [Dasgupta et al., 2000], where they are involved in activating and down-
modulating immune responses and combining the humoural and cell mediated immunity 
[Takai, 2005]. The Fc-receptor-mediated uptake of liposomes by macrophages of the RES 
has been studied extensively [Koning et al., 2001; Koning et al., 2002; Koning et al.,
2003]. Pre-treatment of Kupfer cells with aggregated IgG resulted in a 30 % or 50 % 
reduction of unspecific IgG-liposome binding, depending on the grafted position of the 
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antibody; either to the tip of the PEG chain with a hydrazide anchor or randomly to the 
reactive bilayer lipid through MPB-PE, respectively [Koning et al., 2002]. Apart from the 
Fc-receptor, a scavenger receptor was shown to be involved in the Kupfer cell uptake of 
ILs [Koning et al., 2003]. In comparison, our results showed that 25% of the unspecific 
binding was reduced when the antibody was coupled directly to the activated lipid 
bilayer, indicating that other factors might be involved in the unspecific binding. This 
could be the presence of other scavenger receptors on the activated endothelium. 
Furthermore, the concentration of the blocking antibody could not have been sufficient to 
completely block the unspecific binding.    
 It was also investigated whether lipids could play a role in the unspecific binding 
by adding excess of lipid prior to addition of the liposomes. The results showed that this 
treatment did not reduce the binding of hIgG-CL to the activated endothelium, but on the 
contrary showed a tendency to increase the unspecific binding, indicating that excess lipid 
could render the cell surface stickier. 
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Figure 15. Inhibition of unspecific binding by blocking the Fc-receptor. A) Binding and inhibiting binding 
of FITC-labeled human IgG to activated bEnd3 cells. B) Binding of DiO labeled hIgG-NL to activated 
bEnd3 cells and inhibiting binding using a blocking anti-Fc-receptor antibody or 60 µmol of lipid to 
activated bEnd3 cells.  
An alternative protein coupling technique was applied to improve binding 
selectivity. While the NgPE-anchor coupled the proteins directly to the surface of the 
liposome, the cyanur-PEG2000-PE anchor attached the protein to the terminal end of the 
PEG chain [Bendas et al., 1999]. This grafted position of the homing device has been 
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shown to decrease the unspecific interactions at the membrane surface [Kessner et al.,
2001].
Liposomes were prepared with various proteins coupled to the PEG terminus via 
cyanur-PEG2000-PE anchor. First, the binding efficiency of liposomes carrying anti-
VCAM mAb (D-VCAM-CL) to 2F2B cells was compared to liposomes carrying a human 
IgG of irrelevant specificity (hIgG-CL). The targetability of the two different liposomal 
preparations to activated 2F2B cells was analyzed in a fluorescence micro-plate assay. D-
VCAM-CL bound with significantly higher intensity (p<0.001) to the activated 
endothelial cells when compared to control liposomes, as illustrated in Fig. 16A. Binding 
was also analyzed by flow cytometry. Flow cytometry has the advantage that the 
interrogation of single cells in solution represents more accurate data and gives better 
signal-to-background ratios by eliminating background fluorescence remaining in the 
well after washes [Robinson, 2004].  
Results and Discussion 
______________________________________________________________________________________ 
D -VCAM-CL hIgG-CL
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
***
A
rb
it
ra
ry
 f
lu
o
re
s
c
e
n
c
e
 u
n
it
s
a-VCAM-CL hIgG-CL
0
10
20
30
40
50
***
A
rb
it
ra
ry
 f
lu
o
re
s
c
e
n
c
e
 u
n
it
s
V
C
A
M
-C
L
D
rI
gG
-C
L
hI
gG
-C
L
A
lb
-C
L
0
5000
10000
15000
20000
25000 **
A
rb
it
ra
ry
 f
lu
o
re
s
c
e
n
c
e
 u
n
it
s
V
C
A
M
-C
L
D
rI
gG
-C
L
hI
gG
-C
L
A
lb
-C
L
0
25
50
75
100
125 ***
A
rb
it
ra
ry
 f
lu
o
rs
c
e
n
c
e
 u
n
it
s
NgPE-L Cyanur-L
0
500
1000
1500 ***
A
rb
it
ra
ry
 f
lu
o
re
s
c
e
n
c
e
 u
n
it
s
A
B
C D
E
62 
Figure 16. The in vitro targeting of cyanur liposomes to VCAM-1 expressing 2F2B cells and bEnd3 
cells A: Plate reader analysis comparing the binding efficiency of Į-VCAM directed IL with hIgG-
IL to 2F2B cells. B: FACS analysis of the binding efficiency of anti-VCAM directed ILs (D-
VCAM-CL), ILs with human IgG (hIgG-CL) of irrelevant specificity to 2F2B cells, *** p< 0.001 
D-VCAM-CL vs. hIgG-CL. C: Comparison of the targetability of D-VCAM-CL, rIgG-CL, hIgG-CL 
and Alb-CL to activated bEnd3 cells analyzed by fluorescence based cell assay ** p< 0.005 D-
VCAM-CL vs. all three control liposome populations. D: FACS analysis of the binding efficiency of 
anti-VCAM directed ILs (D-VCAM-CL), ILs with coupled rat IgG1 (rIgG-CL) or human IgG 
(hIgG-CL) of irrelevant specificity and albumin (Alb-CL) to bEnd3 *** p=0.001 D-VCAM-CL vs. 
all three control liposome populations. E: Comparison of the binding efficiency of VCAM- targeted 
IL coupled with different anchors NgPE and cyanur-PEG-PE determined by fluorescence based cell 
assay *** p=0.001 NgPE vs. the Cyanur anchor. Data points represent the average of at least three 
experiments, error bars are SD.  
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Indeed, the VCAM-mediated binding of D-VCAM-CL was confirmed and showed 
a 4-fold higher binding in comparison with the negative control (Fig. 16B). Coupling the 
antibody to the liposome via the cyanur anchor seemed to be the most successful. 
Therefore, the same experiments were repeated on activated bEnd3 cells. Additionally, 
two accessory controls that included albumin and isotype matched rat IgG1 antibody 
conjugated to the liposomes were enrolled in the study. The fluorescence micro-plate 
assay showed that D-VCAM-CL bound with significantly higher intensity (p<0.005) to 
the activated endothelial cells compared to all three types of control liposomes (Fig. 16C). 
The isotype matched rat IgG1 is, compared to fractionated human IgG, a better control for 
the IgG mediated unspecific binding. There were no differences between binding of the 
purified rat IgG1-conjugated liposomes (rIgG-CL) and the fractionated human IgG-
conjugated liposomes (hIgG-CL) to the target cells. 60-70 % of fractionated human IgG 
has the IgG1 subtype [Hamilton, 1987], and the mouse Fc receptor has been shown to bind 
all IgGs independent of the species [Ober et al., 2001], indicating that the hIgG would 
behave similarly to rIgG1 in circulation. Therefore, due to cost benefits, fractionated 
human IgG was used as a control.  
As an additional negative control, it was shown that, Į-VCAM-CL did not bind to 
a VCAM-negative control cell line (A2780, data not shown), suggesting that the VCAM-
mediated targeting was specific. Flow cytometry analysis confirmed the VCAM-mediated 
binding and showed a higher binding in comparison to negative controls (Fig. 1D; p< 
0.001).
Finally, Į-VCAM liposomes with the two different anchors were compared 
against each other in a micro plate assay. As illustrated in Fig. 16E, the VCAM targeted 
cyanur-coupled liposomes showed a significantly higher binding efficiency compared to 
the NgPE liposomes (p < 0.001). The difference was not caused by differences in the 
amount of protein coupled to the liposomal surface. Table 1 shows that the liposome 
populations used were comparable in size and protein coupling. Therefore, it is unlikely 
that any differences in targeting behavior were related to liposomal physical 
characteristics.
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Particle size 
(nm) 
Polydispersity Pg protein/ Pmol PL 
Protein
content/molecule 
per liposome 
D-VCAM-NL 83.1 ± 14.4 0.13 ± 0.05 54.8 ± 35.5 63.1 ± 52.0 
hIgG-NL 91.3 ± 13.2 0.12 ± 0.06 69.9 ± 51.6 70.1 ± 53.2 
D-VCAM-CL 83.1 ± 14.4 0.13 ± 0.05 59.0 ± 17.9 52.3 ± 15.8 
rIgG-CL 93.4 ± 12.0 0.15 ± 0.04 67.0 ± 51.8 68.2 ± 36.1 
hIgG-CL 91.3 ± 13.2 0.12 ± 0.06 74.4 ± 40.2 71.1 ± 35.2 
Alb-CL 84.5 ±13.1 0.15 ± 0.06 70.3 ± 42.0 85.0 ± 4.31 
Table 1: Comparison of the liposomal characteristics with respect to particle size and protein coupling 
yield 
The superior behavior of the cyanur liposomes could be explained by the position 
of the grafted protein. Proteins coupled to the tip of the PEG chain might have better 
access to the target compared to proteins that are coupled directly to the surface of the 
liposomes and therefore are partly masked by the PEG chains [Maruyama et al., 1995]. 
Finally the cyanur anchor was chosen as the best in achieving a VCAM-mediated binding 
and all further IL preparations in this work contain this anchor. The data confirm specific 
targeting of ILs via VCAM in two different cell models. Since both cell lines displayed 
identical targeting behavior, one cell line was chosen for further experiments. bEnd3 cells 
were selected because of their easier cultivation conditions with respect to safety 
requirements. 
3.1.2.1 Internalization of VCAM-targeted liposomes by activated endothelium 
To gain further insight into the behavior of the liposomes after binding to the 
endothelial cells, liposomal internalization was investigated. As illustrated in Fig. 17 
(upper panel) the total association of liposomes with the activated endothelial cells 
increased with time; from 30 min to 2 hours, whereas the amount of liposomes that were 
internalized reached a maximum after 1 hour.
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Figure 17. Internalization of DiO labeled Į-VCAM liposomes by activated endothelial cells. The binding 
and internalization, depicted in the upper panel (top), and percentage endocytosis, in the lower panel 
(bottom), of Į-VCAM liposomes was determined as a function of time at 37 ºC. 
Calculating the percentage of internalized liposomes showed that after 30 min 
approx. 24 % of the total liposomes associated with the cells were internalized, but after 2 
hours the amount of internalized liposomes compared to total cell associated liposomes 
was reduced to 8 % (Fig. 17, lower panel). These results suggest that the Į-VCAM-CL
were initially internalized rapidly, but reached a plateau after 1 hour. The fate of the 
VCAM receptor after antibody binding is, as mentioned before, controversial [Kuijpers et
al., 1994; Ricard et al., 1998]. One study showed that monoclonal antibodies against 
VCAM remained on the surface of HUVEC cells 20 min after binding [Kuijpers et al.,
1994], whereas another study found that Į-VCAM antibodies were rapidly internalized 
and that 50% of the antibody was internalized after 11.2 min by HUVEC cells [Ricard et
al., 1998]. VCAM-targeted nanoparticles are also internalized. Voinea et al. [2005] 
showed that VCAM-targeted liposomes were internalized after binding to activated 
HUVECs [Voinea et al., 2005] and a phage display-derived peptide with homology to the 
Į-chain of VLA-4 was used to internalize nanoparticles into the endothelial cells via 
VCAM as a way to amplify signals (“biological amplification through intracellular 
trapping “) [Kelly et al., 2005]. The bEnd3 cells internalized Į-VCAM-CL and reached a 
plateau after 1 hour (Fig. 17, upper panel); in contrast, HUVECs were shown to increase 
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the amount of internalized liposomes from 1 to 24 hours [Voinea et al., 2005]. The 
discrepancy between these two studies could be due to the different time frames. After 1 
hour the internalizing mechanism might have been saturated, and the bEnd3 cells could 
after 24 hours have internalized a bigger fraction of the Į-VCAM-CL. Another 
explanation could be that VCAM behaves differently in murine endothelial cells 
compared to human endothelial cells.  
 The experiment showed that a fraction of the liposomes were internalized after 
binding to the endothelium. Whether the internalization was a passive or active process 
was not investigated. However, previous studies have shown that VCAM internalization 
occurs via clatrin-mediated endocytosis [Ricard et al., 1998; Voinea et al., 2005].
The liposomes in this study are used to target TNF-Į and DMXAA to the endothelium. 
TNF-Į exerts its activity through TNFR60 which is expressed on the cell surface; the 
release of TNF-Į at the endothelial surface is therefore preferable. However, a study 
showed that delivering TNF-Į to the TNF-Į resistant human cancer cells via internalizing 
ILs induced TNF-Į cytotoxicity [Morishige et al., 1993], suggesting that TNF-Į is also 
cytotoxic when delivered intracellulary.   
3.1.3 The targeting of activated endothelium in a dynamic flow assay  
Static binding of liposomes to the cell surface does not mimic the vascular 
targeting of liposomes under physiological shear force conditions in circulation, 
especially considering the highly variable flow conditions in tumor vasculature 
[Denekamp et al., 1985]. 
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Figure 18. Binding of rhodamine-labeled D-VCAM-CL to stimulated bEnd3 cells under shear force 
conditions illustrated in a phase contrast image (left), as a fluorescence image (middle) and as an overlay 
image (right). The binding of rhodamine-labeled Į-VCAM-CL to the cell monolayer was analyzed at 0, 1 
and 20 hours (A-C) and compared to the binding of rhodamine- labeled hIgG-CL after 20 hours (D). The 
bar represents 50 µm. 
Therefore, we employed a flow chamber assay [Kessner et al., 2001] to 
investigate whether liposome binding was sufficient to target bEnd3 cells under shear 
stress conditions similar to those found in capillary venules. The binding of D-VCAM-CL
and hIgG-CL to endothelial cells was followed microscopically over a time period of 20 
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hours. As shown in Fig. 18 A-C, the binding of D-VCAM-CL to the cell layer increased 
in a sustainable manner illustrated by the increasing fluorescence intensity with time. In 
contrast, no binding was observed with the hIgG-CL (Fig. 18D). The staining of the 
bEnd3 cells (Fig. 18C) represents both internalized and surface-bound liposomes. The 
ratio of surface-bound and internalized ILs was not determined, and should be 
investigated further. 
Dynamic flow based analysis of endothelial adhesion is mainly used to investigate 
the interactions between leukocytes and endothelial cells [Florey and Haskard, 2007]. 
However the technique has also been used to study liposomal interaction with endothelial 
cells. Previous studies targeted liposomes to the adhesion molecule, E-selectin, under 
shear stress conditions [Bendas et al., 1998; Kessner et al., 2001]. Antibody-based 
vascular targeting strategies are more advantageous because the antibody/antigen binding 
exhibits excellent bond dissociation constants; however it also has potential problems. 
One problem is the relatively low bond formation rates between antibody and antigen, 
which could hamper the attachment of rapidly transiting particles in shear stress where 
contact time is short [Kaufmann et al., 2007]. The dynamic binding studies proved that Į-
VCAM-CLs were able to target VCAM on activated endothelium in a circulation relevant 
time range despite the shear stress. The dynamic flow assay also offers the advantage of 
being a method that mimics the conditions in circulation and reduces the number of 
animal experiments.  
  The in vitro studies showed that Į-VCAM-CLs target activated endothelium 
successfully under both static and dynamic conditions. After binding, internalization of 
the Į-VCAM-CLs was observed. Targeting ILs to VCAM on activated HUVEC cells has 
previously been investigated in vitro [Chiu et al., 2003; Voinea et al., 2005]. VCAM is a 
convenient target as it is found up-regulated on activated endothelium. Furthermore, Į-
VCAM nanoparticles have been used to detect areas of early inflammation [Tsourkas et
al., 2005] and in vivo detection of atherosclerotic lesions [Kelly et al., 2005; Kaufmann et
al., 2007]. The VCAM nanoparticles could therefore be suitable candidates for a variety 
of therapies and as imaging agents.  
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3.2 In vivo targeting of VCAM-1 expressed on tumor endothelium 
Since the in vitro results appeared promising, the vascular targeting of D-VCAM-
CL was investigated in mice bearing human Colo 677 xenograft tumors.
3.2.1 VCAM expression on the vasculature of the human Colo 677 xenograft 
model
The Colo 677 tumor model has previously been investigated by Dienst et al.
[2005] and has been shown to express VCAM on the endothelium. The Colo 677 cells 
form solid tumors when injected subcutaneously, although Colo 677 cells are myeloma 
cells that normally would not form solid tumors. However, in this model, ~30% of the 
tumor vasculature is VCAM-positive. The model was chosen because the expression of 
VCAM is generally low on blood vessels in other tumor mouse models, in contrast to 
tumor vascular VCAM expression in humans [Dienst et al., 2005]. 
Figure 19. VCAM expression by tumor endothelial cells in a human Colo 677 xenograft tumor. 
Immunohistochemical staining showed that VCAM (Fig. 19) was expressed throughout the tumor in a 
vessel-like pattern confirming the previous results [Dienst et al., 2005]. For our purpose the expression of 
VCAM on the endothelium is more important than the origin of cancer cell, therefore this tumor model was 
chosen for targeting and therapy experiments.  
3.2.2 Tumor distribution of 3H-labelled targeted and non-targeted liposomes 
The intra-tumor accumulation of D-VCAM-CL versus hIgG-CL 30 min and 24 
hours after i.v. injection, was quantified by detecting the [
3
H]-labeled liposomes in the 
tumor tissue. The data given in Fig. 20 indicate that the accumulation of both liposomal 
populations increased with time. At 24 hours, about 2% of injected dose per gram of 
tissue was localized to the tumor, although – in contrast to human tumors - only ~30% of 
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tumor vessels show a medium strong expression of VCAM-1 in this mouse model [Dienst 
et al., 2005].
30 min 24 hours
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Figure 20. Comparison of the quantitative tumor accumulation of D-VCAM-CL and hIgG-CL. The [3H]-
activity in tumors was detected 30 min and 24 h after injection of the [3H]-labeled liposomes into Colo 677 
tumor xenograft mice (data are means ± SD, n  4).  
The tumor accumulation of VCAM-directed ILs was slightly higher than that of 
control liposomes, but this difference did not reach statistical significance. This was not 
unexpected and should be related to unspecific tumor accumulation of the control 
liposomes. Unspecific accumulation of liposomes has been described previously [Huang 
et al., 1992; Emanuel et al., 1996; Charrois et al., 2003] and is attributed to an EPR effect 
[Noguchi et al., 1998].
 The accumulation of doxorubicin-loaded liposomes targeted against polyoma 
virus-induced tumor associated antigen showed an accumulation of approximately 3 % 
ID/g tissue after 6 hours in mice bearing stage 1 A9 lung metastasis [Emanuel et al.,
1996], even though the time frame was different, this is comparable to the accumulation 
found in our study. However, other studies showed that approximately 5-8 % of both 
targeted and non-targeted liposomes accumulated in the tumor after 24 hours [Marty et
al., 2002; Maeda et al., 2004; Kirpotin et al., 2006; Pastorino et al., 2006]. The difference 
might be attributed to the fact that the Colo 677 tumor model only expresses VCAM on 
approximately 30 % of the endothelium, resulting in a lower accumulation. It might also 
be case that different tumor model exhibit a different degree of EPR.
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The differences between unspecific and specific tumor targeting of liposomes cannot be 
distinguished by quantitative evaluation. Therefore experiments were performed to 
investigate the specific localization of the liposomes after injection.  
In order to evaluate whether vascular-directed versus unspecific ILs were
localized to different compartments within the tumor, we investigated the targeting 
behavior of DiO-labeled ILs by fluorescence microscopy. The images, in Fig. 21 clearly 
indicate that tumor accumulation of D-VCAM-CL was evident after only 30 min (Fig. 
21A1) and had increased by 24 hours (Fig. 21B1). At both time points the tumor 
accumulation of D-VCAM-CL was more intense than that of both control liposomes (Fig. 
21C1-D1), which was unexpected when considering the data in Fig. 20. The lower 
fluorescence intensity of the control liposomes in the tumors could be related to a higher 
degree of extravasations and dilution of the liposomes throughout the tumor which 
renders their fluorescence below the detection level.  
To confirm whether the different liposomes were localized to the tumor 
vasculature, tumor sections were counterstained with a fluorescent antibody against 
murine CD31 (Fig. 21A2-D2). This double labeling procedure (Fig. 21A3 and B3 low 
magnification, A6 and B6 high magnification) revealed a clear co-localization between 
the D-VCAM-CL and the endothelium after 30 min (91.7%) and after 24 hours (73.1%). 
In contrast, both types of control liposomes displayed a much lower degree of co-
localization with vascular endothelium (30.3% and 23.7%, resp.; Fig. 21 C3-D3 low 
magnification, C6-D6 high magnification). Endothelial cells are known to express 
receptors for the Fc portion of antibodies [Olafsen et al., 2006] as well as for albumin 
[Antohe et al., 1991]. Labeling activated endothelial cells with a negative control IgG-
antibody coupled to nanoparticles has been described in a mouse model for vascular 
inflammation [Tsourkas et al., 2005]. This background binding could probably be 
decreased if recombinant antibody fragments devoid of the Fc portion, such as scFv, were 
to be used as a targeting moiety.  
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Figure 21. Localization of the different liposome populations within the tumors. (A1-6) D-VCAM-CL 30 
min after i.v. injection; (B1-6) D-VCAM-CL 24 h after i.v. injection; (C1-6) hIgG-CL 24 h after i.v. 
injection; (D1-6) Alb-CL, 24 h after i.v. injection illustrating a high degree of co-localization for A and B, 
but not for C and D. 1) liposome distribution (green), 2) endothelial staining with CD31 (red), 3) overlay at 
low magnification, 4) liposome distribution (green), 5) endothelial staining with CD31 (red), 6) overlay at 
high magnification of liposome distribution (green) and endothelial marker CD31 (red). The bar in the low 
magnification images corresponds to 50 Pm. The bar in the high magnification images corresponds to 5 Pm. 
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Similar studies investigating the distribution of tumor vasculature targeting 
liposomes showed that the peptide SP5-52 accumulated in lung tumors by recognizing the 
tumor neo-vasculature [Lee et al., 2007]. However, this study only investigated the 
localization of the homing peptide and lacked investigations of the whole liposomal 
particle. Another example is a nano-particle containing iron oxide that targeted clotted 
plasma proteins. This nano-particle was found localized to the tumor endothelium, but 
only after pretreatment with Ni
2+
-liposomes. Ni
2+
and iron oxide are thought to attract 
plasma opsonins and deplete opsonins from circulation, thereby increasing the circulation 
time of the nanoparticles [Simberg et al., 2007].
These data indicate that the D-VCAM-CLs behave differently from the unspecific 
tumor accumulation of non-targeted liposomes, supporting the effort to develop a specific 
and receptor-mediated vascular targeting. In a similar study, Kirpotin et al. [2006] 
investigated the distribution and localization of liposomes targeted against tumor cells 
compared to non-targeted liposomes. Their results showed that although approximately 
the same amounts of liposomes were found in the tumor, the specific localization of the 
liposomes differed. The non-targeted liposomes accumulated in the perivascular and 
extracellular space, whereas the targeted liposomes were found in the tumor cell cytosol 
[Kirpotin et al., 2006]. Knowledge about the cellular distribution within the tumor is an 
important factor when choosing an appropriate effector molecule.  
3.2.3 The localization of liposomes in organs 
To investigate whether D-VCAM-CL would target vasculature outside the tumor, 
the localization of the liposomes in major organs, such as heart, lung, liver, spleen and 
kidney, was investigated. The biodistribution of the liposomes was quantitatively 
determined using both [
3
H]-labeled D-VCAM-CL and hIgG-CL with subsequent activity 
detection in the organs after 30 min and 24 hours. After 30 min, the majority of Į-
VCAM-CL was localized in the liver (16.3 % ID/g) and the spleen (11.5 % ID/g); 
whereas the organ distribution was much lower in the other organs. The same was seen 
for the hIgG-CL. Although there was a difference in the amount of liposomes 
accumulated in the liver and the spleen for the two types of liposomes it was not 
significant due to high standard deviations. There was also no difference observed for all 
other organs except the blood, where the difference between the levels of Į-VCAM-CL 
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(15.7 %) and hIgG-CL (4.4 %) was statistically significant (p = 0.008). This was not 
excepted and is most likely explained by technical difficulties in the 30 min series, which 
was also evident by the large standard deviation found in the liver and spleen. Heart 
puncture could have been the wrong blood sampling technique to use after 30 min or 
might have been carried out wrongly. Another explanation could be that the liposomes 
where still localized in the tail. In further experiments the radioactivity in the tail should 
be measured as a control. 
Muscle Skin Heart Lung Kidney Spleen Liver Blood
D-VCAM-L
30 min 
24 hours 
0.25 ± 023 
0.25 ± 0.18 
0.86 ±0.69 
0.69± 0.45 
0.72± 0.56
1.03± 0.67 
0.94± 0.56 
1.85± 0.94 
1.21 ± 0.40 
3.59 ± 2.14 
11.5 ± 7.3 
3.40± 2.32 
16.3 ± 7.9 
8.11± 1.24 
15.7 ± 4.5
1.02± 0.82 
hIgG-L
30 min 
24 hours 
0.34 ± 0.07 
0.46 ± 0.14 
0.86 ± 0.40 
0.99± 0.53 
0.3 ± 0.25 
0.97± 0.37 
0.52± 0.35 
1.66± 0.13 
1.21 ± 0.14 
2.65± 1.73 
3.04± 1.79 
3.30 ± 0.3 
8.01± 2.20  
6.72± 2.20 
4.40± 0.95
1.11± 0.39 
Statistics
(p =) 
30 min 
24 hours
0.55 
0.130 
1
0.42 
0.302 
0.893 
0.293 
0.747 
1
0.546 
0.140 
0.931 
0.135 
0.285 
0.008 
0.864 
Table 2: Biodistribution of D-VCAM-CL and hIgG-CL after 30 min and 24 hour as % injected dose per 
gram tissue. 
The data given for the 24 hours point indicate that the majority of liposomes were 
accumulated in the liver (8% ID/g), followed by kidney, spleen, and lung, whereas other 
organs showed lower liposome accumulation. High uptake into liver, spleen and lung was 
not unexpected, since localization of liposomes into these organs is a well known 
phenomenon and is generally attributed to extraction via the RES [Emanuel et al., 1996]. 
No statistically significant differences were seen between VCAM targeted liposomes and 
control liposomes after 24 hours, consistent with unspecific accumulation being part of 
the liposome elimination pathway. This is different from previous reports with both 
NGR-targeted and RGD-targeted liposomes, which accumulate in higher amounts in lung 
and/or spleen [Pastorino et al., 2003; Schiffelers et al., 2003]. 
To define the tissue compartments to which the liposomes localized within the 
different organs, a similar study as the one described above was carried out. Cryosections 
of lungs, kidneys, liver and spleen from mice injected with DiO labeled liposomes (Fig. 
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22A-D, left images) were counterstained with fluorescent antibodies detecting either 
endothelial cells (Fig. 22A-D, middle) or tissue resident macrophages (Fig. 22A-D, right). 
Liposome signals in the lung were rare and, if present, co-localized primarily with 
alveolar macrophages (Fig. 22A, right). Fluorescent signals in the kidney were observed 
in glomeruli, occasionally on endothelial cells, in tubuli and as scattered events. 
Glomerular staining could be explained by VCAM expression of mesangial cells [Seron 
et al., 1991]. In contrast to human kidneys [Kuzu et al., 1993], endothelial cells in murine 
kidneys show a low level of VCAM expression [Fries et al., 1993 and Gottstein C., 
unpublished data]. The tubular stain appeared more diffuse possibly due to free dye 
reabsorbed by the tubuli after escaping into the glomerular filtrate. Scattered staining was 
found within tubular lumina, and also in co-localization with kidney macrophages (Fig. 
22B, right). 
The liver sections exhibited a clear co-localization between the liposomes and 
liver macrophages (Fig. 22C, right image), while virtually no co-localization was 
observed in sections stained against the endothelium (Fig. 22C, middle). Accumulation of 
liposomes in the liver has been studied extensively [Gabizon and Papahadjopoulos; 1988; 
Papahadjopoulos et al., 1991] and the Kupfer cells have been shown to play an important 
role in removing liposomes from circulation [Huang et al., 1992; Litzinger et al., 1994]. 
In the spleen, liposome signals were prominent in the marginal zone, in accordance with 
previous studies [Litzinger et al., 1994; Aichele et al., 2003]. No co-localization with 
spleen vasculature was observed (Fig. 22D, middle). Instead, co-localization was 
observed with F4/80 positive macrophages in the red pulp (not shown) and with CD11b 
positive cells (Fig. 22D, right). CD11b is a marker for macrophages and also for dendritic 
cells, which are known to express VCAM.  
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Figure 22. Distribution of liposomes in lung, kidney, liver and spleen from tumor bearing mice, 24 hours 
after i.v. injection. A: Lung section showing the D-VCAM-CL distribution (left), lung section double-
stained against the endothelial marker Meca32 (middle) and double-stained against the macrophage marker 
CD11b (right). Note that the liposomes in the lung are co-localized with the lung macrophages. B: Kidney 
section showing the distribution of D-VCAM-CL (left); kidney section double-stained against the 
endothelial marker CD31 (middle); kidney section double-stained against the macrophage marker CD11b 
(right). C: Liver section illustrating the D-VCAM-CL (green) distribution (left). Liver section double-
stained against the endothelial marker Meca32 (middle) and liver section double-stained against the 
macrophage marker F4/80 (right). Note the clear co-localization between the liver macrophages and 
liposomes. D: Spleen section showing the distribution of VCAM-CL (green) in the white pulp and marginal 
zone (left). Spleen section double-stained against the endothelial marker Meca32 (middle) and spleen 
section double-stained against the macrophage and dendritic cell marker CD11b (right). The bar in the low 
magnification images corresponds to 50 Pm. The bar in the high magnification images corresponds to 5 Pm. 
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The VCAM-targeted liposomes were shown to not co-localize with the 
endothelium in the major organs investigated in this study. The accumulation observed in 
the spleen and liver were excepted as these are the organs involved in the clearance of 
liposomes from circulation [Blume et al., 1993; Maryama et al., 1995]. Attempts have 
been made to reduce the RES-mediated clearance such as depleting the RES for 
macrophages by pretreatment with clodrante liposomes or opsonin chelating Ni
2+
-iron
oxide nanoparticles [Simberg et al., 2007]. Saturating the RES with lipid [Sharma and 
Sharma, 1997; Simberg et al., 2007] or blocking the Fc receptors [Aragnol and Leserman, 
1986] are other methods that were proven efficient in prolonging the circulation time of 
therapeutic liposomes [Aragnol and Leserman, 1986; Simberg et al., 2007], resulting in a 
greater targeting potential. In our study the major concern was that the drugs encapsulated 
in the liposomes induce coagulation and vascular collapse and therefore a co-localization 
with the vasculature in other organs would not be desirable.   
The VCAM-targeted liposomes were shown to target the tumor vasculature but 
not the vasculature of other organs, thereby the Į-VCAM-CL show potential as a drug 
delivery system for drugs that are aimed at the tumor vasculature. 
3.3 TNF-Į and DMXAA induced cytotoxicity and TF expression 
and activation in vitro
The next step was to find the effector molecule(s) to encapsulate into the targeted 
liposomes. The cytokine, TNF-Į, was chosen as a proof of concept drug, as it was shown 
to induce coagulation in tumors [Watanabe et al., 1988]. The small molecule VDA, 
DMXAA, was also investigated as it is a TNF-Į inducing drug that is currently 
undergoing clinical phase II trials. TNF-Į is known to exhibit multiple effects such as 
permeabilizing the endothelium [Friedl et al., 2002], inducing apoptosis [Pallerdy et
al.,1999; Deng et al., 2003; Xia et al., 2006] and inducing a pro-coagulative state by the 
induction of TF [Bevilacqua et al., 1986; Conway et al., 1989]. Therefore, in vitro studies 
were conducted to investigate the cytotoxic effect of TNF-Į and DMXAA on murine 
endothelial cells. Thereafter the expression and activity of TF induced by TNF-Į and 
DMXAA was studied.
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3.3.1 TNF-Į and DMXAA induced cytotoxicity on endothelial cells 
The primary goal of our study was to induce TNF-Į mediated clotting in tumors. 
However, TNF-Į and DMXAA have also been shown to exert a direct cytotoxic effect on 
human endothelial cells [Xia et al., 2006]. 
3.3.1.1 TNF-Į induced cytotoxicity 
A simple PI uptake assay and a MTT proliferation assay were used to study the 
TNF-Į induced cytotoxicity. The cytotoxicity of TNF-Į was first investigated using a 
crude assay that measures changes in the plasma membrane [Darzynkiewics et al., 1997]. 
PI is a membrane impermeable dye, which only stains those cells whose membranes have 
become permeable by i.e. TNF-Į induced cell damages. The PI method is based on the 
binding of the fluorescent PI to nucleic acids [Wrobel et al., 1996].  
As shown in the dot plots (Fig. 23B and D) the percentage of PI positive cells increased 
with time from 27.11% at 24 hours to 76.99% at 48 hours. These results indicate that 
TNF-Į induces cell death in murine endothelial cells.
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Figure 23. The uptake of PI after of TNF-Į treatment on bEnd3 endothelial cells after 24 and 48 hours. A: 
PI stained not stimulated bEnd3 cells after 24 hour. B: PI stained bEnd 3 cells stimulated with 100 ng/ml 
TNF-Į after 24 hours. C: PI stained not stimulated bEnd3 cells after 48 hour. D: PI stained bEnd 3 cells 
stimulated with 100 ng/ml TNF-Į after 48 hours. R1 represents the still living, not stained cell fraction and 
R2 represents the dead or damaged (stained) cell fraction. The analyzed regions are representative for at 
least three similar experiments. 
Apoptosis is generally regarded as the opposite of necrosis. Cell necrosis is a 
passive degeneration of cells characterized by swelling of cells and organelles and loss of 
electrolytes balance followed by rupture of the cell membrane [Darzynkiewics et al.,
1997]. Necrosis is often technically defined by the permeability of dyes such as PI and 
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trypan blue, due to membrane rupture. However, in in vitro assays the apoptotic cells are 
not phagocytosed by cells of the immune system, which in turn results in the degeneration 
of apoptotic cell membrane that thereby become permeable for these dyes, a process 
called “secondary necrosis” [Pallerdy et al., 1999]. The PI positive cells in this 
experiment could therefore be both necrotic and late apoptotic cells. Another method to 
study apoptosis and necrosis using flow cytometry is given by analyzing the cell size 
using the forward scatter counts (FSC). During the process of apoptosis, the cells shrink, 
leading to a decrease in the FSC. As seen in Fig. 23B and D the PI positive cells have 
lower FSC, indicating cell shrinkage and thereby apoptosis. However, additional assays 
are necessary to more precisely differentiate between apoptosis and necrosis. This could 
simply be done by pre-incubating the cells with annexin V. Annexin V binds selectively 
to PS in the presence of Ca
2+
, which is present on the outer membrane of early apoptotic 
cells [Vermes et al., 1995].
 The PI assay showed that the percentage of dead cells increased with time. To 
investigate the cytotoxicity of TNF-Į in a dose dependent manner a MTT assay was 
employed. The MTT assay does not measure cell death directly but cell viability, thereby 
giving an indirect measure for cell killing. 
The bEnd3 cells were treated with increasing concentrations of TNF-Į for 6, 24 and 48 
hours. After 6 hours (Table 3) nearly no cytotoxicity was seen independent of the 
concentration. After 24 hours, approximately 30% of the bEnd3 cells were killed by 100 
ng/ml TNF-D, and after 48 hours the number of killed cells increased to 80%. Treatment 
with 10 ng/ml TNF-Į was also cytotoxic towards the bEnd3 cells, after 24 hours 15% of 
the cells were killed and after 48 hours 70 % were killed.
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ng/ml % survival 
6 hours 
% survival 
24 hours 
% survival 
48 hours 
0 99.89 ± 28.72 99.88 ± 16.20 101.33 ± 15.65 
10 100.50 ± 3.77 85.15 ± 4.30 33.68 ± 6.13 
100 82.32 ± 8.90 71.13 ± 7.95 22.71 ± 10.17 
Table 3: The cytotoxic effect of TNF-Į on bEnd3 cells. The percentage of surviving cells at different 
concentration in the time range 6-48 hours 
The MTT assay is widely used to measure cytotoxicity of agents used in anti-
cancer treatment. TNF-Į was previously shown to kill approximately 40% of bovine 
pulmonary arterial endothelial cells at a concentration of 20 ng/ml [Polunovsky et al.,
1994], or 40 % of HUVECs using 40 ng/ml TNF-Į after 24 hours [Xia et al., 2006]. After 
24 hours the bEnd3 cells exhibited a lower degree of cytotoxicity (a15 % - 30%) 
compared to the two studies described above. However the use of different doses 
complicates a direct comparison. TNF-Į is not cytotoxic to most cells, because activation 
of the TNFR60 also leads to the activation of NF-NE and JNK signaling pathway [Lee et
al., 1997], which protects the cells against the apoptotic effect of TNF-Į [Deng et al.,
2003]. Co-treatment with inhibitors of protein synthesis by i.e. actinomycin D and 
cyclohexamide, which inhibits transcription and translation respectively, enhances the 
cytotoxicity of TNF-Į [Polunovsky et al., 1994]. Thus, de novo synthesis of apoptosis 
protecting proteins seems to be essential for the protective effect of NF- NE. Treatment 
with TNF-Į for 48 hours seems to be cytotoxic independent of the dose. The results 
presented here give no explanation for this. However, it might be that after 48 hour the 
amount of TNF-Į induced ROS has increased to such a degree leading to a ROS mediates 
inactivation of NF- NE [Deshpande et al., 2000]. This is very speculative and the 
mechanism is not known, however another study showed that appox 78 % of bovine 
adrenal cortex-derived microvascular endothelial cells were apoptotic after 48 hours of 
exposure to 1 µg/ml TNF-Į [Lucas et al., 1998] corresponding well with the results in the 
present study. Further studies are needed to clarify the mechanism.   
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The two assays, PI and MTT, showed the same tendency namely that after 24 
hours about 30% and after 48 hours about 70 % of the cells are killed, confirming that 
both assay can be used to study the TNF-Į induced cytotoxicity.
3.3.1.2. DMXAA induced cytotoxicity 
The cytotoxic effect of DMXAA on endothelial cell was also studied using the 
bEnd3 cells. The cytotoxicity assays of TNF-Į on bEnd3 cells showed that TNF-Į did not 
induce cell death after 6 hours. Therefore, the DMXAA induced cytotoxicity was studied 
after 24 and 72 hours of treatment. DMXAA showed a dose dependent cytotoxicity on 
bEnd3 after 24 and 72 hours (Table 4).
DMXAA
(µg/ml) 
% survival 
24 hours 
% survival 
72 hours 
0 100 ± 3.77 100 ± 6.18 
 100 50.97 ± 1.34 76.49 ± 11.14 
1000 34.89 ± 2.81 43.09 ± 6.68 
Table 4: The cytotoxic effect of DMXAA on bEnd3 cells. The percentage of surviving cells at different 
concentration after 24 and 72 hours 
The greatest cytotoxic effect was seen after 24 hours. Treatment with 100 µg/ml 
DMXAA resulted in killing of approx. 50% of the cells, and 1 mg/ml resulted in 65% 
dead cells. However, after 72 hours the percentage of viable cells was increased, 
indicating that especially for low doses of DMXAA, the cells recover from 24 to 72 
hours. The cytotoxicity of DMXAA on endothelial cells in vitro has been investigated 
using the TUNEL assay in another study. After 24 hours a dose of 400 µg/ml DMXAA 
induced apoptosis in approximately 40% of murine endothelial cells [Ching et al., 2002]. 
Two different methods were used to determined cell death, which might be the reason for 
the discrepancy between these two studies. The TUNEL assay labels apoptotic cells, 
whereas the MTT assay illustrates the cell viability but does not distinguish between 
apoptotic and necrotic cells.
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Apart for being cytotoxic against endothelial cells, the cytotoxic effects of 
DMXAA on tumor cells are controversial. DMXAA was not cytotoxic against RIF-1 cells 
[Bellnier et al., 2003], but approx 10 µg/ml DMXAA was shown to inhibit cell growth in 
70Z/3 and 1.3E2 pre-B lymphoma cells [Woon et al., 2003]. In both cases the 
cytotoxicity of TNF-Į on the tumor cells was investigated and it was found that the tumor 
cell death was not affected by TNF-Į [Bellnier et al., 2003; Woon et al., 2003]. The 
cytotoxic effects of DMXAA seen in the two pre-B lymphoma cell lines was independent 
of TNF-Į, indicating that DMXAA might exhibit some direct cytotoxic activities 
dependent on the tumor cell.   
3.3.2 TNF-Į induced TF expression and activity 
Among several effects, TNF-Į is known to induce the expression of TF. Since the 
expression of TF is of central importance in our targeting approach, we first wanted to 
study the TNF-Į effect on TF expression in the bEnd3 cell system. The relationship 
between TNF-Į and TF up-regulation has been described before, but most studies were 
carried out on human endothelial cells [Rehemtulla et al., 1991; Kim et al., 2001; 
O’Reilly et al., 2003]. In this work a murine model was used and therefore an 
investigation of the effect of TNF-Į on murine endothelial cells was needed.  
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Figure 24. TNF-Į induced tissue factor expression on bEnd3 cells investigated by Western blot and cell-
based ELISA. A: Immunoblot of bEnd3 cells either stimulated (1) with 50 ng/ml TNF-Į for 6 hours or not 
treated (2). B: tissue factor expression on bEnd 3 cells that where either not activated or treated with 50 
ng/ml TNF-Į for 6 hours; compared to B16 cells that constitutively express tissue factor. *** p = 0.001 no 
activation vs. TNF-Į treated cells. Data points represent the mean of at least three experiments, error bars 
are SD.  
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Western Blot analysis of stimulated and not stimulated bEnd3 cells showed that 
both treatments resulted in an expression of TF protein. The band representing the 
activated cells (Fig. 24A) seems to be stronger than the band representing the control 
cells, when taking into account that the same amount of total protein was added to each 
well. However, to be able to quantify the increase, a cell-based ELISA was developed 
where the immunoreaction was carried out on top of fixed cells. As illustrated in Fig. 
24B, the stimulated bEnd3 cells showed a 3-fold increase in the TF expression. Untreated 
cells showed a basal level of TF expression, which was not unexpected as previous 
studies on human endothelial cells also found that the same [Kim et al., 2001; O’Reilly et
al., 2003]. B16F10 myeloma cells (B16 cells) have previously been shown to express TF 
constitutively [Amarzguioiu et al., 2006]. Therefore, they were included as a positive 
control and were shown to express a slightly increased amount of TF compared to the 
TNF-Į treated bEnd3 cells.
Cell-based ELISAs have previously been used for detection and quantification of 
molecules expressed on the cell surface [Wewetzer et al., 1996; Liu et al., 2000; Yang et
al., 2006]. The advantages of cell-based ELISA are that it is a rapid method for screening 
for surface antigens [Arunachalam et al., 1990; Sedgwick and Czerkinsky, 1992; Liu et 
al., 2000], it is convenient for large scale screening [Wewtzer et al., 1996] and a quick 
test prior to further analysis by more discriminating methods, such as flow cytometry 
[Sedgwick and Czerkinsky, 1992]. In addition, another advantage is that adherent cells 
are not detached from the plate by trypsination or other detachment methods, which might 
enzymatically remove epitopes crucial for antibody binding [Gaffar et al., 1989] or 
induce cellular stress and thereby reducing or increasing the antibody binding. Fixation of 
cells is also known to interfere with the antigen/antibody binding [Wewetzer et al., 1996]. 
In this study the cells were fixed with 1% paraformaldehyde, which was found to be 
optimal with respect to keeping the cells bound to the plate and at the same time retaining 
antigen/antibody binding. The cell-based ELISA has the disadvantage of not directly 
measuring the TF expression on every single cell, but instead gives an average of the total 
increase in TF for the whole cell population. Therefore, to investigate the TF expression 
on single cells, flow cytometry analysis was carried out.
 As shown in Fig. 25, FACS analysis confirmed that TNF-Į induced TF expression 
at a significant level. Furthermore, TF expression was again observed on the control cells. 
To assure that the TF antibody binds specifically to the TF protein, the reaction was 
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spiked with recombinant mouse tissue factor protein (50 µg/ml). This resulted in a 
blockage of the TF antibody/antigen reaction confirming that the detected binding was 
specific towards the TF protein. However, blockage did not completely abolished 
binding, which could indicate that the TF antibody also exhibited unspecific binding. 
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Figure 25. Tissue factor expression on bEnd3 cells treated with TNF-Į or DMXAA. bEnd3 cells treated 
with plain medium, TNF-Į (50 ng/ml) for 6 hours or DMXAA (100 µg/ml) for 12 hours were subjected to 
flow cytometry analysis. The specificity of the TF antibody/TF antigen was tested by spiking the reaction 
with excess TF protein. * P< 0.05 not treated vs. TNF-Į and DMXAA treated. ¤¤ p< 0.001 TNF-Į vs. 
blocked. Data points represent the mean of at least three experiments, error bars are SD.  
For further control, a similar experiment was carried out using the human ovarian 
cancer cell line (A2780Adr), which is negative for mouse TF. Only a slight unspecific 
binding was detected (results not shown). The antibody towards murine TF was of 
polyclonal nature. Polyclonal antibodies are known to exhibit a higher background 
binding compared to monoclonal antibodies [Lipman et al., 2005] and this might explain 
the unspecific binding seen in these experiments. 
 In addition, the expression of TF on bEnd3 cells after treatment with DMXAA 
was studied. The biochemical target of DMXAA is unknown but it has been shown to 
induce the synthesis of TNF-Į, which might lead to the up-regulation of TF either as a 
primary or secondary effect. The cells were treated with DMXAA for 12 hours and a 
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significant up-regulation of the TF expression, comparable to that TNF-Į, was seen (Fig. 
25). This is the first study showing that treatment of endothelial cells with DMXAA 
results in an up-regulation of TF. However, this was expected as DMXAA is known to 
induce the synthesis of TNF-Į. The question is whether the induced TF is the result of 
TNF-Į dependent or independent action of DMXAA. Further studies are needed to clarify 
this.
 The protocols for both cell-based ELISA and flow cytometry have been 
thoroughly optimized. It was previously shown in mouse 3T3 cells [Gregory et al., 1989] 
and COS-7 cells transfected with human TF [Mackman et al., 1990] that expression of the 
TF gene was induced by serum through the regulatory element called serum response 
element [Mackman et al., 1990]. Therefore, the experiments were carried out with cells in 
serum starved medium (1% FCS), which was found to reduce the expression of TF in the 
control cells (not shown). Another problem was that the detachment process seemed to 
activate the cells. It was previously hypothesized that the detachment induces stress in 
cultured cells thereby resulting in a rapid up-regulation or decryption of TF expression 
[Maynard et al., 1975]. Subsequently, all TF expression experiments were carried out on 
attached cells, which were detached after the immunoreaction and right before flow 
cytometry measurement.   
TF is the primary cellular inducer of coagulation and acts as a high affinity 
receptor for factor VII /VIIa. Apart from inducing coagulation, TF also has other distinct 
functions such as participating in inflammation [Mackman, 1995], metastasis [Bromberg 
et al., 1995; Hjortoe et al., 2004], tumor associated angiogenesis [Zhang et al., 1994; 
Contorino et al., 1996] and embryonic development [Carmelit et al., 1997]. The TNF-Į
induced TF expression is regulated by the TNFR60, which in turn activates the 
transcription factors NF-NE [Moll et al., 1995; Matschurat et al., 2003]. Cytokine 
activation might induce changes in cell surface expression of TF by changing gene 
transcription, mRNA stability, translation and protein trafficking [Hansen et al., 2001]. 
The TNF-Į mediated TF up-regulation was found to be dependent on an increased 
transcription of TF mRNA in HUVECs [Conway et al., 1988] and human dermal micro 
endothelial cells (HDMEC) [O’Reilly et al., 2003]. An enhanced transcription might be 
assumed as the mechanism involved in the TNF-Į induced up-regulation in bEnd3 cells. 
The signaling pathway involved in the induction of TF after TNF-Į treatment varies 
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depending on the cell line [O’Reilly et al., 2003] but it is beyond the scope of this study 
to investigate the signaling pathways involved in TNF-Į mediated TF in bEnd3 cell. 
 It has been hypothesized that cells express encrypted TF protein, which does not 
have full clotting activity and needs to be decrypted to regain full activity [Bach and 
Rifkin, 1990; Bogdanov et al, 2005]. Therefore a simple coagulation assay was developed 
to roughly validate that the up-regulated TF indeed was active.
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Figure 26. Coagulation time induced by tissue factor activity on bEnd3 cells treated with TNF-Į or 
DMXAA or on B16 cells. B16 cells were used as positive control cell line. bEnd3 cells were treated with 
TNF-Į (50 ng/ml) for 6 hours, DMXAA (100 µg/ml) for 12 hours or plain medium. TF mediated clotting 
was abolished with a TF antibody. *** p =0.0006 B16 vs. B16 + Į-TF. * P< 0.05 no stimulation vs. TNF-Į
and DMXAA. Data points represent the mean of at least three experiments, error bars are SD.  
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 The cells were stimulated with TNF-Į for 6 hours or with DMXAA for 12 hours 
before cell lysis. The cell lysate was mixed with citrated mouse plasma and after addition 
of Ca
2+
 the change in absorption at 405 nm was observed. As illustrated in Fig. 26, 
clotting time decreased when stimulating the bEnd3 cells with DMXAA (26.8 sec.) or 
TNF-Į (28.0 sec.) compared to non-stimulated endothelial cells (60 sec.). This indicates 
that the up-regulated TF indeed was active. Again the B16F10 cells were included in the 
experiment as a positive control and also showed a strong clotting potential that could be 
delayed by blocking with a TF antibody. This also confirms that the rapid clotting activity 
indeed was TF specific. Blocking the bEnd3 cells activated with TNF-Į also resulted in 
an increased clotting time. However, the deviation in these experiments was rather high 
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and the differences between the clotting times for blocked and not blocked were not 
statistically significant. 
 Although this clotting assay has several restrictions and only allows for a crude 
evaluation of the clotting intensity, it confirms the active state of the TF protein expressed 
by the bEnd3 cells. Blood clotting induced by bEnd3 cells has previously been 
investigated [Dienst et al., 2005; Bhattacharjee et al, 2007]. The targeting of truncated TF 
to the bEnd3 cell surface induced coagulation in a cell-free two-stage coagulation assay 
[Dienst et al., 2005] confirming that bEnd3 cells could be made pro-coagulant. Also, LPS 
stimulated bEnd3 cells were subjected to a cell-free single-stage clotting assay, which 
resulted in a clotting time of 145 sec, whereas non-treated cells exhibited a clotting time 
of 200 sec [Bhattachajee et. al., 2007]. Compared to the presented results, the clotting 
times obtained in the other study were considerably longer, however this could be due to 
the different treatments (TNF-Į and LPS) and different measurement methods. Other 
assays which directly determine the activity of factor VII or X were not performed, but 
could have been useful to more fully characterize the TF activity. 
 The TNF-Į and DMXAA induced clotting time reduction correlates well with the 
up-regulation of TF. The normal bEnd3 cells were shown to express a basal level of TF. 
TF is thought to exist encrypted on the surface of endothelial cells also in culture [Bach 
and Rifkin, 1990; Pendurthi et al., 2007]. Decryption of TF is thought to be mediated by 
modulation of the cell surface in a calcium dependent manner. The precise mechanism of 
TF-decryption is unclear, but the presence of PS on the outer cell membrane [Bach and 
Rifkin, 1990; Henriksson et al., 2005] and changes to the TF protein itself [Henriksson et
al., 2005; Pendurthi et al., 2007] have been suggested as the mechanism. As shown above 
TNF-Į and DMXAA induce cell death, which results in the translocation of PS from the 
inner leaflet to the outer leaflet of the membrane, indicating that activation of the 
endothelium both leads to cell death and at the same time to the induction of a pro-
coagulant state. There is evidence that apoptosis correlates with a pro-coagulant state and 
TF activity [Bombeli et al., 1997; Matschurat et al., 2003], which together might lead to 
the induction of endothelial apoptosis and vascular collapse. 
In conclusion, TNF-Į upregulated and activated TF protein on bEnd3 cells. At 
sites of inflammation and in tumors the cells produce VEGF, which in synergy with TNF-
Į have been shown to up-regulate TF expression [Kim et al., 2001; Shen et al., 2001]. 
Preliminary studies showed that cells treated with both TNF-Į and VEFG expressed a 
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higher amount TF on the cell surface (data not shown). The delivery of TNF-Į to the 
tumor endothelium, could therefore together with the endogenous tumor VEGF lead to 
increased TF expression and clotting.  
3.4 Combing VCAM-targeted liposomes and induction of TF 
activity 
Specific targeting of Į-VCAM liposomes to the tumor vasculature was achieved 
and it was shown that both, TNF-Į and DMXAA are capable of inducing an increased TF 
expression and pro-coagulant activity in murine endothelial cells. The next step was 
therefore to combine the two parts and to investigate the anti-tumor effect of Į-VCAM 
targeted liposomes carrying either TNF-Į or DMXAA in vivo. First, the encapsulation of 
the two agents was investigated. 
3.4.1 Encapsulation of TNF-alpha and DMXAA into ILs 
Liposomes encapsulated with TNF-Į and DMXAA were formulated and 
characterized. In order to encapsulate sufficient amount of drugs, another method of 
liposome preparation was used. A 100 mM concentration combined with small volumes 
excluded the use of extrusion. The liposomes were instead sonicated to achieve the right 
size. However, this method has a lower reproducibility with respect to particle size. As 
seen in Table 5, the particle size was slightly increased and so was the polydispersity, 
compared to the empty liposomes used in the targeting studies (Table 1).
Particle 
size(nm) 
Polydispersity 
Encapsulation 
efficiency (%) 
TNF-Į -L 109 ± 2.3 0.294 ± 0.027 33.04 ± 10 
DMXAA-L 110 ± 1.8 0.306 ± 0.04 18.02 ± 3.7 
Table 5: Comparison of the liposomal characteristics with respect to particle size and encapsulation 
efficiency.
Results and Discussion 
______________________________________________________________________________________ 
90 
The amount of encapsulated TNF-Į was determined with FITC-labeled TNF-Į,
whereas the determination of the DMXAA concentration was based on direct 
measurements of the fluorescent drug. A fluorescence spectrum was obtained and the 
optimal wavelength for excitation and emission were 350 nm and 412 nm, respectively. 
This was nearly identical to the wavelengths used by Zhou et al. [2001] who used an 
excitation wavelength of 345 nm and an emission wavelength of 409 nm. 
Fluorescence measurements showed that about 33% of TNF-Į was encapsulated, 
which is in agreement with other studies, where encapsulation efficiencies were around 
24% [ten Hagen et al., 2002]. Using the reverse phase evaporation method to prepare the 
liposomes, a much higher encapsulation efficiency of 63 % was achieved [Morishige et
al., 1993]. Former studies focused whether the liposomal TNF-Į was partly bound non-
covalently to the outer membrane of the liposome. The association efficiency of native 
TNF-Į to preformed liposomes was 3.9 % [Utsumi et al., 1991], suggesting that TNF-Į
also might unspecifically associate with the liposomal membrane. However, this fraction 
appears tolerable and should not significantly influence the liposomal behavior. 
Modifications of the cytokine itself, by i.e. increasing its lipophilicity, can also increase 
the encapsulation efficiency, as shown in a study by Utsumi et al. [1991].
The encapsulation efficiency of DMXAA was approximately 18 %, which was 
lower compared to the encapsulation efficiency of TNF-Į, but not unexpected. DMXAA 
is a small molecule and a weak acid that is ionized at pH 7.4 [Rewcastle et al., 1991; 
Zhou et al., 2001]. DMXAA has therefore a low tendency to associate with the membrane 
and subsequently a lower percentage load of DMXAA is expected. Permeability studies 
in Caco-2 cells showed that DMXAA had a high permeability coefficient and that it was 
transported by passive diffusion over the cell membrane [Zhou et al., 2005]. This makes 
DMXAA a difficult drug to encapsulate in liposomes, as it will leak out of the liposomes 
following its concentration gradient. This explains the low encapsulation efficiency. New 
DMXAA derivatives are under investigation, where lipophilic groups are added to the 
molecule [Gobbi et al., 2006]; more lipophilic molecules might display a higher 
encapsulation efficiency. 
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3.4.2 Treatment of tumor xenografts with TNF- Į and DMXAA loaded VCAM-
targeted liposomes
After successfully targeting Į-VCAM liposomes to the tumor vasculature, 
experiments were designed to combine the targeting with the clotting potential of TNF-Į
or DMXAA. VCAM targeted and non-targeted TNF-Į or DMXAA loaded liposomes 
were injected into mice bearing Colo 677 xenografts.  
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Figure 27. Effect of different treatments with targeted and non-targeted TNF-Į and DMXAA encapsulated 
liposomes on tumor growth of Colo 677 xenografts in mice. 10 animals per group were treated with either 
rIgG TNF-L (0.5 mg TNF-Į/ kg), Į-VCAM TNF-L (0.5 mg TNF-Į/ kg) or Į-VCAM DMXAA-L (7 mg 
DMXAA/kg). One group was not treated. One-way analysis of variance resulted in P< 0.001 *** P< 0.001 
not-treated and rIgG TNF-Į-L vs. Į-VCAM TNF-Į-L; ** P< 0.05 not treated vs. Į-VCAM DMXAA-L and 
P<0.01 rIgG TNF-Į-L and Į-VCAM DMXAA-L. Each data point is an average of at least 9 mice; error 
bars are SD. 
The two drugs have previously been shown not to induce complete tumor 
regression, but a delay in tumor growth or shrinkage of the tumor volume. The delay in 
tumor growth was selected as the experimental read-out, and the time was recorded which 
was needed for the tumor to reach 5 times its original size at treatment. As illustrated in 
Fig. 27 the treatment with Į-VCAM TNF-Į-CL and Į-VCAM DMXAA-CL delayed the 
tumor growth time compared to that of tumors treated with rIgG-TNF-Į-CL and animals 
that received no treatment. The growth delay was greatest for tumors treated with targeted 
TNF-Į-CL (approximately 4 days longer than control), but the difference between the two 
targeted treatments was not significant (DMXAA 2.7 days). Subsequently, the growth 
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time for the non-targeted TNF-Į liposomes was only slightly increased compared to the 
control group, suggesting that targeting the liposomes to tumor vasculature is necessary 
for TNF-Į to have an effect i.e. by inducing a collapse of the tumor vasculature.  
 This is the first study investigating the anti-tumor effect of targeted TNF-Į
liposomes on xenograft tumors. Previous studies have used sterically stabilized liposomes 
loaded with TNF-Į in the treatment of solid tumors [van der Veen et al., 1998; Yuyamaa 
et al., 2000; Kim et al., 2002a; ten Hagen et al., 2002]. The encapsulation of TNF-Į in 
PEGylated liposomes resulted in an increased circulation time of TNF-Į and an enhanced 
TNF-Į accumulation in the tumor [van der Veen et al., 1998]. TNF-Į loaded liposomes 
were also shown to reduce tumor growth in rats transplanted with T9 gliosacroma cells in 
the time span of 14 days after two treatments [Wakabayashi et al., 1997] and in mice 
bearing Meth A sarcoma tumors [Yuyamaa et al., 2000]. However others found that 
treatment with TNF-Į loaded PEGylated liposomes had no effect on tumor growth alone, 
but enhanced the anti-tumor effect of radiation [Kim et al., 2002b] or doxorubicin [ten 
Hagen et al., 2002] in a synergistic manner. Our results show that one bolus injection of 
VCAM targeted TNF-Į loaded liposomes resulted in a tumor growth delay compared to 
control tumors and tumors treated with non-targeted TNF-Į liposomes. It seems that the 
localization of the liposome in the tumor is of importance to the anti-tumor effect, thus 
this could explain why, in some studies, unspecific accumulation of sterically stabilized 
liposomes had no effect on tumor growth.   
After VCAM binding, the TNF-Į-CL might either release TNF-Į, thereby 
inducing an endothelial effect via the TNFR60 or be internalized and induce endothelial 
cell cytotoxicity [Morishige et al., 1993]. In addition to the direct effect on tumor 
endothelial cells, liposomal TNF-Į has been shown to also have an immuno-modulatory 
effect [Kedar et al., 1997]. Liposomal TNF-Į exhibits an altered biodistribution compared 
free TNF-Į and is eliminated through the liposomal elimination pathway, which leads to 
accumulation in i.e. the spleen and liver. Especially, the accumulation of TNF-Į-
liposomes in the spleen was found to result in a sustained leukocyte recruitment [Kim et
al., 2002b] and activation, which might be an important factor in the additive or 
synergistic anti-tumor effect of liposomal TNF-Į in combination with other cancer 
therapies [Kim et al., 2002a].
 The dose of DMXAA used in this study was considerably lower than the optimal 
dose (7 mg/kg vs. 25 mg/kg). DMXAA is known to have a narrow therapeutic window 
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ranging from 15- 25 mg/kg [Siemann et al., 2002]. However, targeting and encapsulation 
of drugs in liposomes has previously been shown to expand the therapeutic window, 
which could also be the case here. More studies are needed where higher concentrations 
of liposomal DMXAA are administered to investigate, whether a dose above 25 mg/kg is 
tolerated and the therapeutic window expanded.
When comparing these results with the results obtained from the distribution 
experiments with radiolabeled and DiO-labeled targeted and non-targeted liposomes, the 
significance of targeting is emphasized. The difference in tumor growth time could not be 
attributed to the physical properties of the liposomes used in this experiment (Table 6). 
Particle
size(nm) 
Polydispersity
Drug
 µg/ ml 
Coupling 
Pg Ab/ Pmol 
PL
Į-VCAM 
TNF-Į -L 168.5 ± 9.3 0.302 ± 0.07 41.01 181 
rIgG
TNF-Į-L 154.3 ± 3.2 0.350 ± 0.05 39.35 199 
Į-VCAM 
DMXAA-L 
161.0 ± 15.4 0.352 ± 0.04 504.00 96 
Table 6: Characteristics of liposomes used in the treatment experiment. Particle size, amount of drug and 
the coupling efficiency are described. 
The liposome populations used were comparable in size and protein coupling, 
except for the Į-VCAM DMXAA-L which exhibit a lower amount of antibodies coupled 
to the liposomal surface. The particle size of these liposomes was slightly increased 
compared to the liposomes used in the targeting study. This could have an effect on the 
biodistribution of the liposomes but should not interfere with the targeting.  
 The tumor xenograft model Colo 677 has previously been used to study tumor 
growth delay in mice treated with truncated TF targeted to VCAM on the tumor 
endothelium. This showed that the Colo 677 model was suited for long-term treatment 
experiments. Tumor growth was moderately delayed when mice were treated with the 
truncated TF conjugate alone, but in combination with multiple doxorubicin treatments 
tumor growth was inhibited for 14 days [Dienst et al., 2005]. The success of VDAs in 
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anti-cancer treatment is more pronounced when VDAs are used in combination with 
conventional anticancer treatments. 
3.4.2.1 The side effects of liposomal TNF-Į and DMXAA
The use of TNF-Į in cancer treatment is often hampered by multiple side effects 
due to the cytokines systemic effect. The use of liposomal encapsulation has the 
advantage that it may reduce the systemic effect of the drug by altering their organ 
distribution [Debs et al., 1990; Kim et al., 2002a; ten Hagen et al., 2002]. The severe side 
effects seen in mice treated with free TNF-Į result in changes in blood pressure, shock-
like syndrome and death [ten Hagen et al., 2002]. It was therefore important to examine 
the toxic effect of TNF-Į and DMXAA loaded liposomes. One study showed that the 
body weight of rats injected with 0.2 mg/kg free TNF-Į was reduced > 30% [ten Hagen et
al., 2002]. Body weight is a sensitive parameter of systemic TNF-Į induced toxicity. The 
body weight was monitored throughout the whole study and is illustrated in Fig. 28. Body 
weight loss was not detected for any of the TNF-Į treatments, indicating that the mice 
were not suffering from systemic toxicity. 
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Figure 28. Side effect monitoring by following the body weight of the mice during TNF-D treatment. Each 
data point is an average of at least 4 animals. 
The dose of DMXAA administered in this study was relatively low and therefore no 
toxicity was expected. Based on the body weight, mice treated with DMXAA liposomes 
did not develop toxicities. 
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3.4.2.2 Distribution of TNF-Į and TF in the tumors 
To understand the mechanism behind the tumor growth delay and to examine the 
amount of accumulated TNF-Į in the tumor after treatment, a TNF-Į ELISA was applied. 
The TNF-Į ELISA should also quantify the amount of TNF-Į induced by the DMXAA 
treatment.
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Figure 29. Distribution of murine TNF-Į in the tumors using a TNF-Į ELISA. The amount of TNF-Į in the 
tumors was determined after the tumor reached the maximal size. Each data point is an average of at least 9 
mice; error bars are SD 
The amount of TNF-Į in tumors from treated-mice, independent of the treatment, 
was shown to be slightly elevated compared to the control group that received no 
treatment (Fig. 29). However, the differences were not statistically significant. This was 
most likely due to the time point of investigation. All animals were sacrificed after their 
tumors reached a tumor size 5-fold to the treatment size. Therefore, some animals were 
sacrificed after 4 days, and other after 10 days. Thus, it is difficult to compare the groups. 
Another study is needed were animals are sacrificed at certain pre-defined time points 
after injection of TNF- Į or DMXAA loaded liposomes. The accumulation of sterically 
stabilized TNF-Į loaded liposomes in tumors was investigated in a time range of four 
days. The amount of TNF-Į in the tumors was higher in animals receiving liposomal 
TNF-Į compared to animals receiving free TNF-Į and remained elevated for up to 4 days 
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[Kim et al., 2002a]. Confirming that experiments carried out within shorter time intervals 
after treatment are needed. 
 Administration of DMXAA results in an increase in TNF-Į synthesis [Pang et al.,
1998; Joseph et al., 1999]. In the time range of 0 - 4 hours, tumor bearing mice treated 
with DMXAA showed a time-dependent increase in the intratumoral TNF-Į activity 
[Joseph et al., 1999]. Another study found the same increase in TNF-Į protein, which 
peaked after 4 hours, in tumors using a TNF-Į ELISA [Seshadri et al., 2007]. Our results 
showed that there was no difference in the accumulation of TNF-Į between the non-
treated control and DMXAA treated groups either indicating that the dose was too low to 
induce a TNF-Į response or that a too long time had passed since the synthesis of TNF-Į
was peaked. The latter explanation is most likely, as a tumor growth delay was observed 
suggesting that DMXAA had exerted its action the tumor.  
Our hypothesis focused on administration of TNF-Į or DMXAA to induce blood 
coagulation via TF at the tumor endothelium. Therefore immunohistochemistry was 
employed to investigate whether a treatment specific up-regulation of TF on tumor 
endothelium was found. However, the immunohistochemical detection of the TF 
expression in the tumor endothelium was not successful. This is due to the fact that the 
available antibodies were not suited for immunohistochemistry on paraffin embedded and 
paraformaldehyde fixed tissues. Thus, it was not possible to determine the localization of 
TF in tumor sections. 
A pilot experiment was performed where Colo 677 bearing mice were treated with 
VCAM-targeted TNF-Į-CL and sacrificed after 0, 24 or 72 hours. Thereafter, Western 
Blot analysis was used to investigate the TF expression in the tumors. As illustrated in 
Fig. 30, a clear up-regulation of TF protein was seen in tumors after 72 hours (Fig. 30, 
lane 1 and 2) compared to the control tumors (Fig. 30, lane 4 and 5). After 24 hours (Fig. 
30, lane 3) a slight increase in the expression of TF was seen, indicating that treatment 
with TNF-Į loaded liposomes indeed leads to an increased TF expression.
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542 31
TF 45 kDa 
Figure 30. TNF-Į induced tissue factor expression in Colo 677 xenograft tumors 0, 24 and 72 hours cells 
after treatment with Į-VCAM TNF-Į-L investigated by Western blot A: Immunoblot Colo 677 tumors 
either after treatment (1-2) for 72 hours, (3) for 24 hours and (4-5) for 0 hours. 
This study was only preliminary and the amount of mice used was not sufficient to 
exclude coincidences. Despite of that, these results indicate that TF was upregulated after 
TNF- Į-CL treatment, although the specific localization of TF could not be determined.  
TNF-Į is known to induce thrombus and fibrin formation in tumor vasculature in mice 
[Watanabe et al., 1988]. We were not able to show thrombus formation in this study as 
the end-point of the treatment study was tumor growth delay and the tumors had 
recovered from the damages induced by the treatment at the time of scarification. 
However, it was important first to investigate whether the treatments had any effect on 
tumor growth before looking for a molecular reason. The performed pilot experiment 
showed that TF was up-regulated in a time-dependent fashion, which correlates well with 
previous studies. Indirectly, this might indicate that the tumor growth delay could have 
correlated with an up-regulation of TF and induction of coagulation.
3.4.2.3 Induction of apoptosis in tumors treated with TNF-Į or DMXAA-L
The anti-tumor activity of TNF-Į and DMXAA is based on the selective 
destruction of the tumor vasculature leading to a secondary ischemic necrosis of the 
tumor cells [Baguley and Ching, 2002]. Both TNF-Į [Xia et al., 2006] and DMXAA 
[Ching et al., 2002] have been shown, in previous studies and in this study, to have a 
direct cytotoxic activity against endothelial cells. TNF-Į also induces changes in the 
vascular permeability, and after DMXAA treatment, an increased tumor vascular 
permeability was strongly correlated with the induction of TNF-Į [Seshadri et al., 2007]. 
The vascular permeability was associated with changes in cell shape and motility, as well 
as and the expression of TF and adhesion molecules [Friedl et al., 2002]. All together, 
these changes result in vascular collapse. 
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 In order to get a further insight into the mechanism behind the tumor growth 
delay, apoptosis was investigated using a TUNEL assay. As illustrated in Fig. 31 (A-D) 
all four types of tumors obtained from mice treated with either, nothing, rIgG TNF-Į-CL,
Į-VCAM TNF-Į-CL, and Į-VCAM DMXAA-CL contained TUNEL positive cells. 
Control sections that were not treated with the TdT enzyme, were included as negative 
controls for unspecific peroxidase activity (Fig. 31E), implying that the positive reactions 
seen in other sections indeed TdT activity specific. The staining pattern showed a hot spot 
area in the middle of the tumor (Fig 31A-D1; §), corresponding to the necrotic core of the 
tumor. In the periphery of the tumor occasionally similar hot spots were seen. To 
investigate whether there was a quantitative difference in the amount of apoptotic cells 
within the different treatment groups, two different fields were counted from 4 tumors in 
each group. Both fields were in the periphery, one in a hot spot area (*) and one in a 
normal area (#). Counting the positive cells in the cores of the tumors was difficult due to 
the exceeding number of positive cells (Fig. 31A-D 2). As illustrated by the graphs ( Fig. 
31 F and G), the amount of TUNEL positive cells was elevated in the hot spot area of the 
tumor periphery in tumors treated with Į-VCAM TNF-Į-L. In addition, the amount of 
TUNEL positive cells was increased in all groups except the control group in fields from 
the periphery without hot spots. These results indicate that treatment with all liposome 
preparations induced cell death in the tumors. However, the Į-VCAM TNF-Į-CL induced 
more hot spots, which could be due to an increased shut down of in the vasculature after 
this treatment. The results correlate well with the tumor growth delay, where the Į-
VCAM TNF-Į-CL liposomes also induced the greatest response. 
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Figure 31: Apoptosis induced in Colo 677 xenografts after treatment with targeted and non-targeted TNF-Į
or DMXAA loaded liposomes. A) TUNEL stained tumor section from a control mouse 1) at low 
magnification 2) the core of the tumor at high magnification (§). B) TUNEL stained tumor section from a 
rIgG TNF-Į-L 1) at low magnification 2) the core of the tumor at high magnification. C) TUNEL stained 
tumor section from Į-VCAM TNF-Į-L 1) at low magnification 2) the core of the tumor at high 
magnification. D) TUNEL stained tumor section from Į-VCAM DMXAA-L 1) at low magnification 2) the 
core of the tumor at high magnification. E) Control staining without addition of TdT enzyme. F) 
Quantification of TUNEL positive cells per field in fields like the one marked by (*)* p < 0.05 Į-VCAM 
TNF-Į-L vs. the rest. G) Quantification of TUNEL positive cells per field in fields like the one marked by 
(#); p < 0.05 control vs. the rest.  
The TUNEL assay was employed to investigate the apoptotic state of the 
endothelial cells and the tumor cell after administration of the different liposome 
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preparations. It was not possible to determine the origin of apoptotic cells, without double 
staining against i.e. CD31 or a tumor cell antigen. The TUNEL assay sensitively stains 
cells with damaged DNA primarily apoptotic cells, however necrotic cells also exhibit 
DNA fragmentation and the TUNEL assay fails to distinguish between apoptotic and 
necrotic cells [Gras-Kraupp et al., 1995]. Therefore staining represents both the necrotic 
and apoptotic cells. As expected, most tumors were shown to have a necrotic area in the 
middle of the tumor. Stainings in the periphery correlated well with the increased amount 
of TNF-Į found in Fig. 29, indicating that this was not associated with the tumor growth 
delay. On the other hand, treatment with Į-VCAM TNF-Į–CL resulted in an elevated 
number of hotspots in the tumors and an increase in apoptotic cells, which might be 
treatment specific. However, as previously discussed this experiment was performed too 
late and the tumors had properly recovered from most of the TNF-Į and DMXAA-
induced cell damage and death. DMXAA induced apoptosis was determined after 3 hour 
in Colon 38 tumors, where a 12-fold increase compared to tumors in untreated animals 
was found [Ching et al., 2002]. Another study directly investigated the effect of DMXAA 
on the endothelial cells and showed that 4 hours after DMXAA treatment a strong 
TUNEL reactivity was seen in CD31 positive cells, which was virtually absent after 24 
hours [Seshadri et al., 2007].
 Summarized, treatment with Į-VCAM liposomes loaded with either TNF-Į or 
DMXAA were shown to induce a tumor growth delay after one bolus injection. Thus, the 
effect of vascular targeting was clearly evident. It was difficult to determine the 
mechanism for the treatment induced growth delay, as the tumors were excised to late 
after treatment. However, an increase in total tumor TF in mice treated with TNF-Į was 
shown using Western Blot analysis and the amount of apoptotic/necrotic cells was also 
increased in this treatment group, indicating that coagulation might be the mechanism 
behind the tumor growth delay.  
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4. Conclusions 
The tumor vasculature has been recognized as an attractive drug target, and means 
for efficient delivery of payloads to tumor vascular markers are demanded. First, the 
development of a drug carrier system that specifically targets tumor endothelium was 
investigated. We have generated long-circulating ILs targeted to VCAM. The in vitro
targeting studies provides evidence that Į-VCAM-CLs, compared to VCAM-targeted-
NLs, specifically bound to activated endothelial cells in vitro under static and flow 
conditions. The non-targeted NgPE-coupled liposomes exhibited some unspecific 
binding, which could be inhibited by blocking the Fc-receptor. Investigation of the 
vascular targeting in vivo revealed that D-VCAM-CLs, but not controls liposomes, 
effectively targeted tumor endothelial cells. The localization of VCAM-targeted-CLs in 
non-target organs was primarily found in phagocytic cells and not co-localized to the 
vasculature. The RES uptake of the targeted ILs was not significantly higher compared to 
non-targeted ILs. Thus, PEGylated D-VCAM-CLs are candidate drug carriers for delivery 
of vascular specific payloads to tumor vasculature. 
 TNF-Į and the TNF-Į inducing drug, DMXAA, where chosen as they both are 
vascular disrupting agents, which act on the tumor endothelial cells instead of the tumor 
cells themselves. Their anti-tumor action is mediated through occlusion of tumor vessels. 
It was proposed that TNF-Į and DMXAA had a pro-coagulative effect on murine 
endothelial cells in vitro. After 24 hours treatment with both agents, 30 to 50% of the 
murine endothelial cells were killed providing evidence that both agents exhibit a direct 
cytotoxic effect on endothelial cells. The hypothesis that TNF-Į induced a pro-
coagulative state in endothelial cells through the up-regulation of TF was investigated. 
Stimulation of murine endothelial cells was shown to induce a TNF-Į and DMXAA 
mediated up-regulation of TF expression and activity in vitro. TNF-Į and DMXAA were 
therefore accepted as candidate drugs for the VCAM-targeted liposomes. 
 TNF-Į and DMXAA loaded Į-VCAM liposomes were formulated and reasonable 
encapsulation efficiencies of 33% and 18%, respectively, were obtained. Treatment of 
Colo 677 tumors with VCAM-targeted TNF-Į or DMXAA loaded liposomes resulted in a 
delay in tumor growth time compared to control mice and mice treated with non-targeted 
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TNF-Į loaded liposomes. The mechanism responsible for the tumor growth delay was 
hypothesized be tumor vessel clotting due to an up-regulation of TF expression and 
activity. Investigation of the tumor tissues from mice used in the growth delay 
experiments with respect to the intra-tumor TNF-Į levels, tumor cell apoptosis and TF 
localization could not sufficiently provide insights into the mechanism behind the tumor 
growth delay. However, clotting induced by up-regulated TF might be assumed. 
Experiments with a different endpoint would have been necessary. However, a pilot 
experiment showed that TF protein was upregulated after 24 and 72 hours and together 
with the in vitro data, this indicates that clotting through the up-regulation of TF could 
have been responsible for the VCAM- targeted TNF-Į or DMXAA liposome induced 
tumor growth delay.  
In summary, sterically stabilized VCAM targeted liposomes loaded with either 
TNF-Į or DMXAA specifically target the tumor vasculature and induce a tumor growth 
delay in mice bearing human xenografts, which might be due to an up-regulation of TF 
expression and activity.  Therefore, the vascular targeting of liposomal drugs aiming at 
interfering with the tumor vascular function appears as very attractive therapeutic 
approach in the anticancer research and will be continued in further studies.  
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